REVIEW

Prognostic and clinicopathological value of PD-LI in colorectal cancer: a systematic review and meta-analysis

This article was published in the following Dove Press journal: OncoTargets and Therapy

Lianzhou Yang^b Rujun Xue^{2,3} Chunhua Pan⁴

¹Radiotherapy Department, Central Hospital of Guangdong Nongken, Zhanjiang, Guangdong, People's Republic of China; ²Institute of Dermatology, Guangzhou Medical University, Guangzhou, People's Republic of China; ³Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, People's Republic of China; ⁴The 1st Ward of the Medical Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, People's Republic of China

Correspondence: Lianzhou Yang Radiotherapy Department, Central Hospital of Guangdong nongken, No. 2, Renmin Avenue, Xiashan District, Zhanjiang, Guangdong 524000, People's Republic of China Tel +861 371 944 7962 Fax +860 759 263 3646 Email yanglianzhoumail@gmail.com



Purpose: The prognostic role of programmed death-ligand 1 (PD-L1) in colorectal cancer remains unclear. We employed a meta-analysis to explore the prognostic value of PD-L1 and to ascertain the relationship between PD-L1 expression and clinicopathological characteristics in CRC patients.

Methods: We systematically searched PubMed, Embase and the Cochrane Library until October 2018. Eligible studies about colorectal cancer that pay attention to PD-L1 expression and studies reporting survival information were included. In order to evaluate the prognostic role of PD-L1 for overall survival (OS) and recurrence-free survival (RFS)/disease-free survival (DFS), Hazard ratio (HR) with 95% confidence interval (CI) was used. Odds ratio (OR) with 95% CI was selected to appraise the correlation between PD-L1 with clinico-pathological characteristics of colorectal cancer patients. Begg's funnel plot was used to assess publication bias.

Results: Twelve studies involving 4344 patients published from 2013 to 2018 were included in this meta-analysis. Pooled results revealed that PD-L1 overexpression was relevant to shorter OS (HR 1.47, 95% CI =1.01–2.15, p=0.04) and shorter RFS/DFS (HR 1.47, 95% CI =1.01–2.15, p=0.04). Moreover, Patients with high expression of PD-L1 associated with inferior tumor stage (OR=0.57, 95% CI: 0.45, 0.74, p<0.0001) and Vascular invasionnegativity (OR=0.75, 95% CI: 0.6, 0.94, p=0.01). But the expression of PD-L1 is not related to age, sex, tumor location, tumor differentiation, pT stage, pN stage, MSI/MMR status.

Conclusion: This meta-analysis revealed that PD-L1 can serve as a significant biomarker for negative prognosis and the adverse clinicopathological features of colorectal cancer and could facilitate the better management of individual patients.

Keywords: PD-L1, colorectal cancer, prognosis, meta-analysis

Introduction

Colorectal cancer (CRC) is the most commonly diagnosed cancer worldwide at present, being the third and fifth leading cause of cancer death in the United States and China, respectively.^{1,2} About 39% of patients were diagnosed with localized stage CRC, for which the 5-year survival rates is 90%. However, the patients diagnosed with the regional and distant-stage disease and the survival rate descend on 71% and 14%.³ New treatments for primary, regional and metastatic CRC have been developed, including laparoscopic surgery for primary; resection of the liver and lungs metastatic disease; radiotherapy for rectal cancer and some forms of metastatic disease; neoadjuvant and palliative chemotherapy; targeted therapy,

OncoTargets and Therapy 2019:12 3671-3682

3671

© 2019 Yang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-mc/3.0/). By accessing the work you hereby accept the firms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php). immunotherapy, and vaccines.^{4,5} Therefore, it is critical to early detection, the effectiveness of prevention, and management to improving treatment strategies and patient outcomes.

However, some locally advanced and distant metastatic CRC patients lost the chance of surgery, so chemotherapy is basically the only option for advanced and metastatic patients: but these have only modest efficacy and are ineffective against distant metastases.^{6,7} Moreover, these treatments generate side effects that can limit their use. In recent years, more attention has been placed on developing immunotherapies, specially programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1).PD-1/PD-L1 is one of the most important co-stimulatory signals; its-mediated immunosuppression is an important part of the dynamic balance of the immune system because it limits the immune response and prevents autoimmune diseases. The present study found that CD274 (PD-L1, B7-H1) was first cloned in 1999.⁸ The expression profiles of CD274 (PD-L1) in human tumors have been revealed.9,10 Hunmantumor-associated APCs include tumor microenvironment dendritic cells (DCs), tumor-draining lymph nodes DCs,^{11,12} macrophages,^{13,14} fibroblasts,¹⁵ and T cells¹⁶ were observed a high level of CD274 (PD-L1) protein expression, except tumor cell. Many studies have found that engagement of PD-L1 with its receptor PD-1 on T cells delivers a signal that inhibits T cell proliferation, resulting in tumor immune evasion.¹⁷ PD-1/PD-L1 immune checkpoint inhibitors have been used to treat melanoma, non-small cell lung cancer, renal cell carcinoma, lymphoma, and bladder cancer.¹⁸ However, the efficacy of immune checkpoint inhibitors for the treatment of CRC is limited. Different research has studied the PD-L1 expression of the prognosis role of CRC; nevertheless, the results were not consistent. Some investigations showed that overexpression of PD-L1 forecasted poor survival in CRC, 19-24 but other investigations presented negative results.25,26

To tackle this problem, we employed meta-analysis to synthetic estimate the value of PD-L1 as a prognostic biomarker, and to clarify the relationship between PD-L1 expression and clinicopathological characteristic in CRC patients.

Materials and methods

This meta-analysis is based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.³⁰ Our research was based on data from previously published studies; thus ethical ratify was unnecessary.

Search strategy

The Cochrane Library, Embase and PubMed were systematically searched. The strategy used was to search for the following words in relevant literature: ("Colorectal Neoplasms" OR "Neoplasms, Colorectal" OR "Colorectal Neoplasm" OR "Neoplasm, Colorectal" OR "Colorectal Tumors" OR "Colorectal Tumor" OR "Tumor, Colorectal" OR "Tumors, Colorectal" OR"Colorectal Carcinoma" OR "Carcinoma, Colorectal" OR "Carcinomas, Colorectal" OR "Colorectal Cancer" "Colorectal Carcinomas" OR OR "Cancer, Colorectal" OR "Cancers, Colorectal" OR "Colorectal Cancers") AND ("CD274" OR "B7-H1" OR "PD-L1" OR "PD-L1" OR "CD274 Antigens" OR "B7-H1 Immune Costimulatory Protein" OR "B7 H1 Immune Costimulatory Protein" OR "B7-H1 Antigen" OR "Antigen, B7-H1" OR "B7 H1 Antigen" OR "PD-L1 Costimulatory Protein" OR "Costimulatory Protein, PD-L1" OR "PD L1 Costimulatory Protein" OR "Programmed Cell Death 1 Ligand 1 Protein" OR "CD274 Antigen" OR "Antigen, CD274" OR "Programmed Cell Death 1 Ligand 1" OR "B7H1 Immune Costimulatory Protein"). To recognize more research, we also retrospect the reference lists of relevant articles.

Selection criteria

The eligible researches were contained in this metaanalysis based on the following criteria: (1) Patients with colorectal cancer confirmed by pathology. (2)Immunohistochemistry (IHC) was used to detect the expression of PD-L1 in colorectal cancer tissue. (3) Studies reported 5-year OS, HR with 95% confidence interval (95% CIs), or reported original survival curves. (4) Their full texts were available. This analysis exclude articles based on the following standards: (1) non-English; (2) animal experiments; (3) comment, letters, review or case reports; (4) deficiency data to report the risk ratios (RR) and 95% confidence interval (95% CI), or the Kaplan-Meier curve could not be extracted. When duplicate publications were identified, only the most complete or most recent article was included.

Data extraction

All relevant articles data were extracted by two independent reviewers (Lianzhou Yang, Rujun Xue). The information was extracted from each study included: first author, country, date of publication, number of patients, duration of follow up, age, histological type of tumor, tumor site, grade at diagnosis, number of patients with PD-L1 positive, cut-off value, antibody, survival data, Kaplan-Meier curves. ALL divergences were settled by discussion and the achievement of consensus.

Quality assessment

According to the Newcastle-Ottawa Scale (NOS), two researchers independently assessed each study for quality. (Lianzhou Yang, Rujun Xue). The NOS maximum possible score is 9 points. Each study included was judged on three perspectives: (I) the selection (representativeness, selection of the non-exposed, ascertainment of exposure and outcome of interest); (II) the comparability; and (III) the ascertainment of either the exposure or outcome of interest (assessment and follow-up). A study that received a score of 6 or higher was considered the high-quality study.

Statistical analysis

The software used in this work was Review Manager Software, Version 5.3 and Stata version12.0. The hazard ratio (HR) with 95% CI was utilized to assess the relationship between the expression of PD-L1 and OS, DFS, and RFS. The merged ORs and the 95% CIs were utilized to quantitatively determine the relationship between PD-L1 and clinicopathological feature of the patient. The heterogeneity between included studies was examined using I² and Q text. If p<0.1 or I²>50%, which demonstrated significant heterogeneity, the fixed effect model was used for meta-analysis. If there was significant heterogeneity, the random model was used. In this analysis, *p*-values <0.05 were considered statistically significant.

Results

Search results

After the primary retrieval, 675 potentially relevant articles were initially identified with three databases searched. After removing 156 duplicates, still 519 studies were identified for the title/abstract; however, 422 manuscripts were excluded for the following reasons: not original papers (eg, case report, review, and meta-analysis), animal studies, not colorectal cancer-related studies, not PD-L1-related studies, irrelevant, or were not published in English. Subsequently, 95 articles remained for further full-text assessment. Thereafter, 36 articles were excluded due to insufficient data, 2 articles lack of survival outcomes, 13 were no-original articles and 7 were unfinished clinical trials. Ultimately, twelve studies^{19–26,31–34} published from 2013 to 2018 were included in this metaanalysis (Figure 1).

Characteristics of included studies

Twelve studies involving 4344 patients published from 2013 to 2018 were included in this meta-analysis. The number of patients in each study arranged from 90 to 1420. The immunochemical staining (IHC) was used to confirm PD-L1 expression oftumor tissues in all studies. Three pieces of research were performed in Western countries and nine kinds of research were implemented in Asian countries. The quality of the selected researches wasassessed by using the Newcastle-Ottawa Scale and found to range from 6 to 8, indicating that the studies were of high quality. Table 1 describes the detailed characteristics of the twelve studies.

Correlation between PD-LI expression and survival

We evaluated the prognostic role of PD-L1 expression of OS, RFS, and DFS. Eight researches (n=3198) reported OS, as significant heterogeneity existed (Cochran's Q, p < 0.00001, I²=88%).Pooled result by random model revealed high expression of PD-L1 was correlated with poor OS than the absence of PD-L1 expression (HR 1.47, 95% CI =1.01-2.15, p=0.04) (Figure 2A). Because heterogeneity existed, subgroup analysis was performed. Subgroup analysis based on different analytical methods, integrated HR for OS was 1.29 (95% CI: 0.90-1.86, p=0.16) (Figure 2B). Elucidating the effect of different cut-off of PD-L1 expression of the results, we performed subgroup analysis stratified by cut-off. When score<4 or cut-off $\leq 5\%$ the heterogeneity was negligible, but there was no statistical significance in all subgroup between PD-L1 expression and overall survival (Figure 3A).

Seven (n=1697) reported RFS/DFS. As significant heterogeneity existed (Cochran's Q, p<0.0001, I²=80%). Pooled result by random model revealed PD-L1 overexpression was associated with shorter RFS/DFS than the absence of PD-L1 expression (HR 1.47, 95% CI =1.01–2.15, p=0.04) (Figure 2C). Because heterogeneity existed, subgroup analysis was performed. Subgroup analysis based on different analytical methods, integrated HR for RFS/DFS was 1.86 (95% CI: 1.10–3.14, p=0.02) (Figure 2D). Elucidating the effect of different cut-off of PD-L1 expression of the results, we performed subgroup analysis stratified by cut-off. When cut-off score <4 or




Figure I Flow chart of the literature search and study selection protocols.

 \leq 5% the heterogeneity was negligible. There was no statistical significance in cut-off >5% or score >4 subgroups between PD-L1 expression and RFS/DFS (Figure 3B).

Correlation between PD-LI expression and tumor clinicopathlogical parameters

Moreover, we investigated the relationship between PD-L1 expression and clinicopathological parameters, including sex, age, tumor location, tumor differentiation, tumor stage, pT stage, pN stage, vascular invasion, MSI/MMR status. The analysis of each parameter includes at least three studies. The merged results demonstrated that PD-L1 expression suggests in patients with poorer tumor stage (OR =0.57, 95%CI: 0.45, 0.74, p<0.0001) and Vascular invasion-negativity (OR =0.75, 95%CI: 0.6, 0.94, p=0.01) (Figure 4). However, there was no association between PD-L1 expression and age (OR =0.95, 95%CI: 0.73, 1.22, p=0.67), sex (OR =0.97, 95% CI: 0.84, 1.13, p=0.72), tumor location (OR =1.12, 95%CI:

0.87, 1.45, p=0.37), tumor differentiation (OR =1.18, 95%CI: 0.94,1.48, p=0.15), pT stage (OR =0.81, 95%CI: 0.44, 1.48, p=0.49), pN stage (OR =0.72, 95%CI: 0.44, 1.17, p=0.18), MSI/MMR status (OR =0.54, 95%CI: 0.16, 1.90, p=0.34) (Figure S1).

Sensitivity analyses

We delete any single study at a time individually, which to assess the stability of the results. The results show that there is no separate study significantly affected the total HRs, this meta-analysis of the results are credible.

Publication bias

The funnel plot did not indicate any evidence of publication bias (Figure 5).

Discussion

The PD-1/PD-L1 pathway has become a promising therapeutic target for various human malignancies, including

Table I Characteristics of the studies included in the meta-analysis	istics of	the studies in	ncluded in the	meta-analysis							
Study	Year	Country	Number of patients	Age	Study period	Follow up Median(M)	Detection method	Cut-off	Antibody	PD-LI positive/ negative	Quality assess- ment
Droeser et al ²⁵	2013	Switzerland	1420	69.9 (30–96)	1987–1996		IHC	Percentages of PD-LI staining	Clone 27A2, ab82059	495/913	8
Hamada et al ¹⁹	2017	NSA	617	68.6±8.8	1976–2012	Patients were	НС	intensity Score ³ 2	Anti-CD274	384/233	ω
						death or			anuoudy, eBioscience		
Koganemaru et _{al³¹}	2017	Japan	235	63 (32–84)	2009–2012	January 1, 2012 52.9 (4.6–78.8)	НС	>5%	SP142	19/216	Ŷ
Lee et al ³³	2016	USA	395	55±15 (18–90)	,	55±40 (0.4–393)	HC	×I<	Clone EIL3N	19/375	6
Li et al ²⁶	2016	China	276	57 (27–85)	2007-2009	61	НС	Score ³ 4	ab174838	138/138	7
Liang et al ²⁰	2014	China	185	52 (29–72)		60	ЧU	Score ³ 4	Polyclonal anti-	102/83	6
									bodies, Santa		
									Cruz		
									Biotechnology		
Saigusa et al ²¹	2016	Japan	06	64 (33–80)	2003-2014	46 (2–139)	НС	Score ³ 2	Clone 27A2	36	6
Shi et al ²²	2013	China	143	59.8±12.5	2006-2007	43 (I–56)	НС	Presence of PD-	Abcam,	64	6
								LI staining	ab58810		
Song et al ²³	2013	China	347	65	2000-2006	(1–122)	IHC	Score ³ I.49, ran-	Abcam		8
								ged from 0 to			
								15.9 (median:			
								2.33)			
Wang et al ³²	2017	China	254	56 (28–75)	2007–2009	42 (21–68)	НС	Percentages of	sp142	46/208	7
								ru-LI stalling			
Wang et al ³⁴	2016	China	262	56.5 (28–75)	2007-2009	43.5 (21–68)	HC	-5%	SP142	54/208	8
Zhu et al ²⁴	2015	China	120	67 (54–80)	2008-2013	39	IHC	Score ³ 4	Abcam	28	7
					1						

•					
Α				Hazard Ratio	Hazard Ratio
Study or subgroup	log[Hazard ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Droeser RA 2013	-0.16	0.02	15.9%	0.85 [0.82, 0.89]	•
Hamada T 2017	0.29	0.18	14.0%	1.34 [0.94, 1.90]	
Li Y 2016	-0.5	0.23	13.0%	0.61 [0.39, 0.95]	
Liang M 2014	0.55	0.21	13.0%	1.73 [1.15, 2.62]	
Saigusa S 2016	0.82	0.4	9.4%	2.27 [1.04, 4.97]	
Shi SJ 2013	0.96	0.32	11.1%	2.61 [1.39, 4.89]	
Song M 2013	0.73	0.22	13.2%	2.08 [1.35, 3.19]	
zhu H 2015	0.83	0.36	10.2%	2.29 [1.13, 4.64]	
Total (95% CI)			100.0%	1.47 [1.01, 2.15]	
Heterogeneity: Tau ² =	0.23; <i>Chi</i> ² =60.35, d	df=7 (I	P<0.0000	1); <i>I</i> ² =88%	0.1 0.2 0.5 1 2 5 10
Test for overall effect	: Z=2.01 (P=0.04)				Favors [PD-L1+] Favors [PD-L1-]
В					
		~-		Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard ratio]	SE		IV, Random, 95% CI	
Droeser RA 2013	-0.08		25.0%	0.92 [0.89, 0.96]	
Hamada T2017	-0.18		20.7%	1.20 [0.86, 1.67]	
Li Y 2016		0.25	17.2%	1.05 [0.64, 1.72]	
Saigusa S 2016		0.41	11.2%	2.46 [1.10, 5.49]	
Shi SJ 2013		0.27	16.3%	2.77 [1.63, 4.71]	
zhu H 2015	-0.37	0.47	9.6%	0.69 [0.27, 1.74]	
Total (95% CI)			100.0%	1.29 [0.90, 1.86]	
Heterogeneity: Tau2=	0.14; <i>Chi</i> ² =24.94, d	df=5 (<i>I</i>	P=0.0001); <i>I</i> ² =80%	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Test for overall effect				,.	
	(Favors [PD-L1+] Favors [PD-L1-]
С				Hazard Ratio	
C Study or Subgroup	log[Hazard ratio]	SF	Weight	Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard ratio]			IV, Random, 95% CI	
Study or Subgroup Koganemaru S 2017	0.86	0.34	14.4%	IV, Random, 95% CI 2.36 [1.21, 4.60]	Hazard Ratio
Study or Subgroup Koganemaru S 2017 Lee LH 2016	0.86 1.28	0.34 0.61	14.4% 9.4%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89]	Hazard Ratio
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016	0.86 1.28 -0.58	0.34 0.61 0.21	14.4% 9.4% 17.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85]	Hazard Ratio
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014	0.86 1.28 -0.58 0.6	0.34 0.61 0.21 0.21	14.4% 9.4% 17.0% 17.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75]	Hazard Ratio
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016	0.86 1.28 -0.58 0.6 1.2	0.34 0.61 0.21 0.21 0.42	14.4% 9.4% 17.0% 17.0% 12.8%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56]	Hazard Ratio
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016	0.86 1.28 -0.58 0.6 1.2 0.55	0.34 0.61 0.21 0.21 0.42 0.27	14.4% 9.4% 17.0% 17.0% 12.8% 15.8%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016	0.86 1.28 -0.58 0.6 1.2 0.55	0.34 0.61 0.21 0.21 0.42	14.4% 9.4% 17.0% 17.0% 12.8%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI)	0.86 1.28 -0.58 0.6 1.2 0.55 0.33	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 17.0% 12.8% 15.8% 13.6% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: Tau ² =	0.86 1.28 -0.58 0.6 1.2 0.55 0.33	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 17.0% 12.8% 15.8% 13.6% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI)	0.86 1.28 -0.58 0.6 1.2 0.55 0.33	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 17.0% 12.8% 15.8% 13.6% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect	0.86 1.28 -0.58 0.6 1.2 0.55 0.33	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 17.0% 12.8% 15.8% 13.6% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi</i> ² =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04)	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% ><0.0001	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect	0.86 1.28 -0.58 0.6 1.2 0.55 0.33	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% ><0.0001	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80%	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi</i> ² =30.24, o : <i>Z</i> =2.03 (<i>P</i> =0.04)	0.34 0.61 0.21 0.42 0.27 0.38	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% P<0.0001 Weight 19.3%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subgroup	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi</i> ² =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) log[Hazard ratio] 0.9 3.13	0.34 0.61 0.21 0.27 0.38 df=6 (<i>f</i> SE 0.35 1.25	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% ⊂<0.0001	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Vang L 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi</i> ² =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) log[Hazard ratio] 0.9 3.13	0.34 0.61 0.21 0.22 0.27 0.38 df=6 (<i>f</i> SE 0.35	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% C <0.0001 Weight 19.3% 4.0% 23.8%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi</i> ² =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) log[Hazard ratio] 0.9 3.13 -0.1	0.34 0.61 0.21 0.27 0.38 df=6 (<i>f</i> SE 0.35 1.25	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% C <0.0001 Weight 19.3% 4.0% 23.8% 15.3%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); / ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Vang L 2016 Wang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi²</i> =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) 10g[Hazard ratio] 0.9 3.13 -0.1 1.05 0.35	0.34 0.61 0.21 0.22 0.27 0.38 df=6 (<i>H</i> SE 0.35 1.25 0.23 0.47 0.34	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% 2<0.0001 Weight 19.3% 4.0% 23.8% 15.3% 19.7%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18] 1.42 [0.73, 2.76]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Vang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Saigusa S 2016	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi²</i> =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) 10g[Hazard ratio] 0.9 3.13 -0.1 1.05 0.35	0.34 0.61 0.21 0.22 0.27 0.38 df=6 (<i>H</i> SE 0.35 1.25 0.23 0.47	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% C <0.0001 Weight 19.3% 4.0% 23.8% 15.3%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); / ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Vang L 2016 Wang L 2017 Total (95% CI) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Saigusa S 2016 Wang L 2016	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi²</i> =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) 10g[Hazard ratio] 0.9 3.13 -0.1 1.05 0.35	0.34 0.61 0.21 0.22 0.27 0.38 df=6 (<i>H</i> SE 0.35 1.25 0.23 0.47 0.34	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% 2<0.0001 Weight 19.3% 4.0% 23.8% 15.3% 19.7%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); l ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18] 1.42 [0.73, 2.76] 1.90 [0.88, 4.07]	Hazard Ratio IV, Random, 95% CI
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Uang M 2014 Saigusa S 2016 Wang L 2017 Total (95% Cl) Heterogeneity: <i>Tau</i> ² = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Saigusa S 2016 Wang L 2016 Wang L 2017	0.86 1.28 -0.58 0.6 1.2 0.55 0.33 0.37; <i>Chi²</i> =30.24, <i>c</i> : <i>Z</i> =2.03 (<i>P</i> =0.04) log[Hazard ratio] 0.9 3.13 -0.1 1.05 0.35 0.35 0.64	0.34 0.61 0.21 0.22 0.27 0.38 <i>df</i> =6 (<i>f</i> 0.35 1.25 0.23 0.47 0.34 0.39	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% ><0.0001 Weight 19.3% 4.0% 23.8% 15.3% 19.7% 17.9% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); <i>I</i> ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18] 1.42 [0.73, 2.76] 1.90 [0.88, 4.07] 1.86 [1.10, 3.14]	Hazard Ratio IV, Random, 95% Cl
Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Liang M 2014 Saigusa S 2016 Wang L 2017 Total (95% CI) Heterogeneity: Tau^2 = Test for overall effect D Study or Subgroup Koganemaru S 2017 Lee LH 2016 Li Y 2016 Saigusa S 2016 Wang L 2017 Total (95% CI)	$0.86 \\ 1.28 \\ -0.58 \\ 0.6 \\ 1.2 \\ 0.55 \\ 0.33 \\ 0.37; Chi^2=30.24, c \\ z=2.03 (P=0.04) \\ 10g[Hazard ratio] \\ 0.9 \\ 3.13 \\ -0.1 \\ 1.05 \\ 0.35 \\ 0.64 \\ 0.25; Chi^2=13.84, c \\ 0.25; Chi^2=13.84, c \\ 0.86 \\ 0.25; Chi^2=13.84, c \\ 0.86 $	0.34 0.61 0.21 0.22 0.27 0.38 <i>df</i> =6 (<i>f</i> 0.35 1.25 0.23 0.47 0.34 0.39	14.4% 9.4% 17.0% 12.8% 15.8% 13.6% 100.0% ><0.0001 Weight 19.3% 4.0% 23.8% 15.3% 19.7% 17.9% 100.0%	IV, Random, 95% CI 2.36 [1.21, 4.60] 3.60 [1.09, 11.89] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 3.32 [1.46, 7.56] 1.73 [1.02, 2.94] 1.39 [0.66, 2.93] 1.71 [1.02, 2.86]); <i>I</i> ² =80% Hazard Ratio IV, Random, 95% CI 2.46 [1.24, 4.88] 22.87 [1.97, 265.06] 0.90 [0.58, 1.42] 2.86 [1.14, 7.18] 1.42 [0.73, 2.76] 1.90 [0.88, 4.07] 1.86 [1.10, 3.14]	Hazard Ratio IV, Random, 95% CI

Figure 2 Forest plot describing the association between PD-LI expression and prognosis of patients with CRC patient. (A) OS; (B) OS by multivariate analysis; (C) RFS/ DFS; (D) RFS/DFS by multivariate analysis.

melanoma, non-small-cell lung cancer, head and neck cancer, Hodgkin's lymphoma, gastric cancer, and urothelial cancer. Some clinical trials have shown that PD-1/PD-L1 blockage could benefit prognosis.^{35–39} Nonetheless, there are no consistent results for the prognostic value of PD-L1 in colorectal cancer patients. Lots researches have indicated that the expression of PD-L1 is correlated with an obviously poor survival,^{19,10–24} while

Α				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard ratio]	SE	Weight	V, Random, 95% Cl	IV, Random, 95% Cl
1.3.1 unclear					
Droeser RA 2013	-0.16	0.02	15.9%	0.85 [0.82, 0.89]	•
Shi SJ 2013	0.96	0.32	11.1%	2.61 [1.39, 4.89]	
Song M 2013	0.73	0.22		2.08 [1.35, 3.19]	
Subtotal (95% CI)			40.1%	1.60 [0.73, 3.51]	
Heterogeneity: Tau ² =0.4	$14 \cdot Chi^2 = 28.28 \ df =$	2 (P<		² =93%	-
Test for overall effect: Z		- (1		0070	
1.3.2 =<5% or score<4					
Hamada T 2017	0.29	0 18	14.0%	1.34 [0.94, 1.90]	
Saigusa S 2016	0.82	0.4	9.4%	2.27 [1.04, 4.97]	
Subtotal (95% CI)	0.02	0.4	23.4%	1.54 [0.97, 2.45]	•
Heterogeneity: <i>Tau</i> ² =0.0	1. Chi2-1 AG df-1	(D-0			•
Test for overall effect: Z		(P=0.	.23), 1 –32	70	
1.3.3 =<5% or score>=	4				
Li Y 2016	-0.5	0.23	13.0%	0.61 [0.39, 0.95]	
Liang M 2014		0.21	13.4%	1.73 [1.15, 2.62]	
zhu H 2015	0.83		10.2%	2.29 [1.13, 4.64]	
Subtotal (95% CI)	0.00	0.00	36.5%	1.31 [0.59, 2.92]	
Heterogeneity: <i>Tau</i> ² =0.4	13. Chi ² =15.10 df-	2 (D-1			-
Test for overall effect: Z		2 (r -	5.0005), 7	-07 /6	
Total (95% CI)			100.0%	1.47 [1.01, 2.15]	◆
	23: Chi ² =60.35. df=	7 (P<	0.00001): <i> </i>	² =88%	
Heterogeneity: Tau ² =0.2		7 (P<	0.00001); <i>I</i>	² =88%	0.01 0.1 1 10 10
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: Z	=2.01 (<i>P</i> =0.04)				0.01 0.1 1 10 10 Favors [PD-L1+] Favors [PD-L1-]
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe	=2.01 (<i>P</i> =0.04)				
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: Z Test for subgroup differe B	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c	if=2 (F	P=0.93); <i>I</i> ² =	=0% Hazard Ratio	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup	=2.01 (<i>P</i> =0.04)	if=2 (F	P=0.93); <i>I</i> ² =	=0%	Favors [PD-L1+] Favors [PD-L1-]
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, o log[Hazard ratio]	lf=2 (F SE	P=0.93); <i>I</i> ² =	⊧0% Hazard Ratio V, Random, 95% Cl	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup diffect B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c	lf=2 (F SE	P=0.93); / ² = Weight 15.8%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI)	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, o <u>log[Hazard ratio]</u> 0.55	lf=2 (F SE	P=0.93); <i>I</i> ² =	⊧0% Hazard Ratio V, Random, 95% Cl	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c log[Hazard ratio] 0.55 icable	lf=2 (F SE	P=0.93); / ² = Weight 15.8%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c log[Hazard ratio] 0.55 icable	lf=2 (F SE	P=0.93); / ² = Weight 15.8%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04)	lf=2 (F <u>SE</u> 0.27	P=0.93); / ² = Weight 15.8% 15.8%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4 Lee LH 2016	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04) 1.28	1f=2 (F SE 0.27 0.61	P=0.93); / ² = Weight 15.8% 15.8% 9.4%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04) 1.28	lf=2 (F <u>SE</u> 0.27	P=0.93); <i>I</i> ² = Weight I 15.8% 15.8% 9.4% 12.8%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI)	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, o log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2	0.61 0.42	P=0.93); / ² = Weight 15.8% 15.8% 9.4% 12.8% 22.2%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: <i>Tau</i> ² =0.0	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, <i>c</i> log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1	0.61 0.42	P=0.93); / ² = Weight 15.8% 15.8% 9.4% 12.8% 22.2%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: <i>Tau</i> ² =0.2 Test for overall effect: <i>Z</i> Test for subgroup differe B <u>Study or Subgroup</u> 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: <i>Z</i> 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: <i>Tau</i> ² =0.0	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, <i>c</i> log[Hazard ratio] 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1	0.61 0.42	P=0.93); / ² = Weight 15.8% 15.8% 9.4% 12.8% 22.2%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, <i>c</i> 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1 =3.54 (<i>P</i> =0.0004)	0.27 0.27 0.42 (<i>P</i> =0.	P=0.93); <i>I</i> ² = Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017	=2.01 (P =0.04) ences: Chi^2 =0.15, o 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df=1 =3.54 (P =0.0004) 0.86	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34	P=0.93); <i>I</i> ² = Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0% 14.4%	 =0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1 =3.54 (<i>P</i> =0.0004) 0.86 -0.58	<pre>If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21</pre>	P=0.93); <i>I</i> ² = Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0%	=0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71]	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1 =3.54 (<i>P</i> =0.0004) 0.86 -0.58	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34	P=0.93); <i>I</i> ² = Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0% 14.4%	 =0% Hazard Ratio IV, Random, 95% CI 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014	=2.01 (<i>P</i> =0.04) ences: <i>Chi</i> ² =0.15, c 0.55 icable =2.04 (<i>P</i> =0.04) 1.28 1.2 00; <i>Chi</i> ² =0.01, <i>df</i> =1 =3.54 (<i>P</i> =0.0004) 0.86 -0.58	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.21	P=0.93); <i>I</i> ² = Weight 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0% 14.4% 17.0%	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014 Wang L 2016	=2.01 (P =0.04) ences: Chi^2 =0.15, o 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df=1 =3.54 (P =0.0004) 0.86 -0.58 0.6	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.21	P=0.93); <i>I</i> ² = Weight 15.8% 15.8% 9.4% 12.8% 22.2% 91); <i>I</i> ² =0% 14.4% 17.0% 17.0%	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.3 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014 Wang L 2016 Subtotal (95% CI)	=2.01 (P =0.04) ences: Chi^2 =0.15, o log[Hazard ratio] 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df =1 =3.54 (P =0.0004) 0.86 -0.58 0.6 0.33	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.38	 P=0.93); I²= Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); I²=0% 14.4% 17.0% 17.0% 13.6% 61.9% 	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 1.39 [0.66, 2.93] 1.33 [0.65, 2.68] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: Tau ² =0.2 Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: Z	=2.01 (P =0.04) ences: Chi^2 =0.15, o 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df =1 =3.54 (P =0.0004) 0.86 -0.58 0.6 0.33 43; Chi^2 =21.24, df =	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.38	 P=0.93); I²= Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); I²=0% 14.4% 17.0% 17.0% 13.6% 61.9% 	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 1.39 [0.66, 2.93] 1.33 [0.65, 2.68] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: $Tau^2=0.3$ Test for overall effect: Z Test for subgroup differed B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Saigusa S 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.4$ Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014 Wang L 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.4$ Test for overall effect: Z	=2.01 (P =0.04) ences: Chi^2 =0.15, o 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df =1 =3.54 (P =0.0004) 0.86 -0.58 0.6 0.33 43; Chi^2 =21.24, df =	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.38	 P=0.93); I²= Weight I 15.8% 15.8% 9.4% 12.8% 22.2% 91); I²=0% 14.4% 17.0% 17.0% 13.6% 61.9% 	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 1.39 [0.66, 2.93] 1.33 [0.65, 2.68] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio
Heterogeneity: $Tau^2=0.3$ Test for overall effect: Z Test for subgroup differe B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.6$ Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014 Wang L 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.4$ Test for overall effect: Z Subtotal (95% CI)	=2.01 (P =0.04) ences: Chi^2 =0.15, o 1og[Hazard ratio] 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df =1 =3.54 (P =0.0004) 0.86 -0.58 0.6 0.33 43; Chi^2 =21.24, df = =0.78 (P =0.43)	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.38 3 (P<	P=0.93); <i>I</i> ² = Weight 15.8% 15.8% 15.8% 2.2% 91); <i>I</i> ² =0% 14.4% 17.0% 17.0% 13.6% 61.9% 0.0001); <i>I</i> ² = 100.0%	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 1.39 [0.66, 2.93] 1.33 [0.65, 2.68] =46% 1.71 [1.02, 2.86] 	Favors [PD-L1+] Favors [PD-L1-]
Heterogeneity: $Tau^2=0.3$ Test for overall effect: Z Test for subgroup differed B Study or Subgroup 1.4.1 unclear Wang L 2017 Subtotal (95% CI) Heterogeneity: Not appl Test for overall effect: Z 1.4.2 =<5% or score<4 Lee LH 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.6$ Test for overall effect: Z 1.4.3 >5% or score>=4 Koganemaru S 2017 Li Y 2016 Liang M 2014 Wang L 2016 Subtotal (95% CI) Heterogeneity: $Tau^2=0.4$ Test for overall effect: Z	=2.01 (P =0.04) ences: Chi^2 =0.15, o log[Hazard ratio] 0.55 icable =2.04 (P =0.04) 1.28 1.2 00; Chi^2 =0.01, df =1 =3.54 (P =0.0004) 0.86 -0.58 0.6 0.33 43; Chi^2 =21.24, df = =0.78 (P =0.43) 37; Chi^2 =30.24, df =	If=2 (F SE 0.27 0.61 0.42 (P=0. 0.34 0.21 0.38 3 (P<	P=0.93); <i>I</i> ² = Weight 15.8% 15.8% 15.8% 2.2% 91); <i>I</i> ² =0% 14.4% 17.0% 17.0% 13.6% 61.9% 0.0001); <i>I</i> ² = 100.0%	 =0% Hazard Ratio <u>IV, Random, 95% CI</u> 1.73 [1.02, 2.94] 1.73 [1.02, 2.94] 3.60 [1.09, 11.89] 3.32 [1.46, 7.56] 3.41 [1.73, 6.71] 2.36 [1.21, 4.60] 0.56 [0.37, 0.85] 1.82 [1.21, 2.75] 1.39 [0.66, 2.93] 1.33 [0.65, 2.68] =46% 1.71 [1.02, 2.86] 	Favors [PD-L1+] Favors [PD-L1-] Hazard Ratio

Figure 3 (A) Subgroup analysis based on a different cut-off of association between PD-LI expression and OS. (B) Subgroup analysis based on a different cut-off of association between PD-LI expression and RFS/DFS.

some study accounted the opposite effect.^{25,26} Several studies have revealed the relationship between PD-L1 and Solid Tumors.^{27–29} However, those studies differs

from our in that their subjects include all solid tumors in which the number of colorectal cancers included too few, and our study provides an in-depth analysis between PD-




Figure 4 Forest plots for the association between PD-L1 expression and clinicopathological parameters. (A) Tumor stage; (B) vascular invasion-negativity.




Figure 5 Funnel plot of publication bias for overall survival.

L1 expression and tumor stage, vascular invasion, MSI/ MMR mutation, etc. In our meta-analysis, we concentrate on the clinicopathological characteristics of patients with colorectal cancer and the prognostic validity of PD-L1 in colorectal cancer.

The interaction between PD-L1 and PD-1 can lead to exhausted phenotype and dysfunction of T-cells which protected tumor cells escape from the host immune surveillance.⁴⁰ Immune-checkpoint blockades become a new way in immunotherapy for cancer and it gradually changes the standard treatment of advanced-stage cancers. According to reports, overexpression of PD-1 and PD-L1 on tumor-infiltrating lymphocytes (TIL) and tumor cells (TC) correlates with poor prognosis in several cancers.⁴¹

overexpression of PD-L1 had poorer overall survival (p<0.001; HR =2.07 (1.342-3.193). But, multivariate analysis did not support PD-L1 as an independent prognostic factor (p=0.548). Otherwise, some similar studies have revealed similar results. In contrast, a study of Droeser et al,²⁵ which involved 1420 CRCs patients, found the patients with MMR-proficient with PD-L1 overexpression correlated with better OS (*p*=0.003; HR =0.84 (0.79–0.88); In univariate analysis, PD-L1 overexpression in MMRproficient CRC was significantly correlated with early T stage, absence of lymph node metastases, lower tumor grade, absence of vascular invasion. Moreover, in the study by Li et al,²⁶ this involved two cohorts; In the TCGA cohort, higher PD-L1 expressions indicated a better OS (p=0.002). In FUSCC cohort, expressions of PD-L1 on tumor cells were associated with better OS (p=0.002) and DFS (p=0.004) of CRC patients. Therefore, a meta-analysis of available data on the prognostic significance of PD-L1 will be useful and imperatively needed. In this meta-analysis, we synthesized twelve pieces of research relevant to prognosis and clinicopathological of PD-

Such as breast cancer.⁴² renal cell cancer.⁴³ lung cancer.⁴⁴

glioma.⁴⁵ In colorectal cancer, this is in agreement with the study by Hamada et al,¹⁹ which indicated the association of

PD-L1 overexpression and poor OS in CRCs (HR 1.33,

95% CI 0.94–1.89). Additionally, Song et al,²³ using tissue

microarray immunohistochemistry to detect 404 CRC

patient samples, univariate analysis disclosed that patients

L1 expression in colorectal cancer. As we know, this is the first meta-analysis focus on the prognosis and clinicopathological characteristics of patients with colorectal cancer. Our data indicated that PD-L1 overexpression was associated with shorter OS (HR 1.47, 95% CI =1.01–2.15, p=0.04) and shorter RFS/DFS (HR 1.47, 95% CI =1.01-2.15, p=0.04), suggesting that PD-L1 expression could serve as an important prognostic factor for colorectal cancer. Related research shows that immune evasion caused by PD-1/PD-L1 pathway may be related to poor infiltration of T cells into tumors and lack activation of cancer-specific T cells in the tumor microenvironment.⁴⁶ Moreover, PD-L1 overexpression was increased in patients with inferior tumor stage (OR=0.57, 95%CI: 0.45, 0.74, p<0.0001) and Vascular invasion-negativity (OR=0.75, 95%CI: 0.6, 0.94, p=0.01). For the present study, we didn't find relationship between PD-L1 expression and age, gender, tumor location, tumor differentiation, pT stage, pN stage, MSI/MMR status.

There were several limitations to our study. Some significant heterogeneity can be observed in our study. These heterogeneities may have different sources. Firstly, only articles published in English were included in this metaanalysis. Secondly, the sample sizes of the studies enrolled in our analysis were comparatively small. Third, PD-L1 positivity was evaluated by using different antibody and dilution which affect the sensitivity of IHC. Fourth, the cut-off value where PD-L1 expressed was varied among the studies. So, future researches should make efforts in the standardization of PDL1 expression detection. Additionally, because not all study has a distinction about MSI/MMR status and not provide sufficient information which may bring heterogeneity to the meta-analysis. Based on our observations, we believe that the results of our meta-analysis should be noticed and should be validated by additional studies with appropriate multivariate analyses.

Our investigation exhibited that the overexpression of PD-L1 indicates a poor prognosis and clinicopathological features and that treatment with anti-PD-L1 antibodies should be attempted in patients with CRCs patient in the future.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin.* 2016;66(2):115–132. doi:10.3322/caac.21338

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387
- Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.21395
- Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
- Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. *Discov Med.* 2013;15(84):301–308.
- Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. *Nat Rev Clin Oncol.* 2015;12(2):73–74. doi:10.1038/nrclinonc.2014.233
- Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin oncol. 2015;33(16):1809–1824. doi:10.1200/ JCO.2014.59.7633
- Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med.* 1999;5(12):1365–1369. doi:10.1038/70932
- Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med.* 2000;192(7):1027–1034.
- Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin oncol.* 2014;32(10):1020–1030. doi:10.1200/JCO.2013.53.0105
- Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nat Med.* 2003;9(5):562–567. doi:10.1038/nm863
- Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. *J Immunol.* 2007;178(5):2763–2769.
- Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. *Cancer Res.* 2009;69 (20):8067–8075. doi:10.1158/0008-5472.CAN-09-0901
- Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206 (6):1327–1337. doi:10.1084/jem.20082173
- Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr., Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. *J Immunol.* 2007;178(9):5552–5562.
- 16. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia (New York, NY)*. 2006;8 (3):190–198. doi:10.1593/neo.05733
- Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin oncol.* 2015;33(9):983–991. doi:10.1200/JCO.2014.58.1967
- Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi:10.1172/JCI80011
- Hamada T, Cao Y, Qian ZR, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin oncol. 2017;35(16):1836–1844. doi:10.1200/JCO.2016.70.7547
- Liang M, Li J, Wang D, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. *Tumour Biol.* 2014;35(1):55–60. doi:10.1007/s13277-013-1006-6
- 21. Saigusa S, Toiyama Y, Tanaka K, et al. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. *Int J Clin Oncol.* 2016;21(5):946–952. doi:10.1007/s10147-016-0962-4

- 22. Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. *PLoS One*. 2013;8(10):e76012. doi:10.1371/journal.pone.0076012
- 23. Song M, Chen D, Lu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. *PLoS One.* 2013;8(6): e65821. doi:10.1371/journal.pone.0065821
- 24. Zhu H, Qin H, Huang Z, et al. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. *Int J Clin Exp Pathol.* 2015;8(8):9351–9359.
- Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur J Cancer*. 2013;49(9):2233–2242. doi:10.1016/j.ejca.2013.02.015
- 26. Li Y, Liang L, Dai W, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. *Mol Cancer*. 2016;15(1):55. doi:10.1186/s12943-016-0539-x
- Wu P, Wu D, Li L, Chai Y, Huang J, Soutto M. PD-L1 and survival in solid tumors: a meta-analysis. *PLoS One.* 2015;10(6):e0131403. doi:10.1371/journal.pone.0131403
- Pyo JS, Kang G, Kim JY. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. *Int J Biol Markers*. 2017;32(1):e68– e74. doi:10.5301/jbm.5000225
- Xiang X, Yu PC, Long D, et al. Prognostic value of PD -L1 expression in patients with primary solid tumors. *Oncotarget*. 2018;9 (4):5058–5072. doi:10.18632/oncotarget.23580
- 30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535. doi:10.1136/bmj.b2651
- Koganemaru S, Inoshita N, Miura Y, et al. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. *Cancer Sci.* 2017;108(5):853–858. doi:10.1111/cas.13229
- Wang L, Liu Z, Fisher KW, et al. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. *Hum Pathol*. 2018;71:20–29. doi:10.1016/j.humpath.2017.07.014
- Lee LH, Cavalcanti MS, Segal NH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. *Mod Pathol.* 2016;29(11):1433–1442. doi:10.1038/modpathol.2016.139
- 34. Wang L, Ren F, Wang Q, et al. Significance of programmed death ligand 1 (PD-L1) immunohistochemical expression in colorectal cancer. *Mol Diagn Ther*. 2016;20(2):175–181. doi:10.1007/s40291-016-0188-1

- 35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
- 36. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol.* 2015;16(3):257–265. doi:10.1016/S1470-2045(15)70054-9
- 37. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087
- Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369 (2):134–144. doi:10.1056/NEJMoa1305133
- 39. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *Lancet Oncol.* 2016;17(7):956–965. doi:10.1016/S1470-2045(16)30066-3
- Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. *Trends Mol Med.* 2015;21(1):24–33. doi:10.1016/j. molmed.2014.10.009
- Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. *Cancer Treat Rev.* 2015;41(10):868–876. doi:10.1016/j.ctrv.2015.11.001
- 42. Guo Y, Yu P, Liu Z, et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis. *PLoS One.* 2016;11(5):e0156323.
- Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. *Int J Clin Exp Med.* 2015;8 (9):14595–14603.
- 44. Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. *Immunotherapy*. 2016;8 (4):479–488. doi:10.2217/imt-2015-0002
- 45. Xue S, Song G, Yu J. The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. *Sci Rep.* 2017;7 (1):4231. doi:10.1038/s41598-017-04023-x
- 46. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–1504. doi:10.1093/annonc/mdw217

Supplementary material

Study or Subgroup	Age= Events	Total	Age> Events	Total		Odds Ratio M-H, Fixed, 95% Cl	Odds Ratio M-H, Fixed, 95% Cl
Koganemaru S 2017	14	134	5	101	4.2%	2.24 [0.78, 6.44]	+
Li Y 2016	85	170	53	106	26.9%	1.00 [0.62, 1.62]	
iang M 2014	40	71	62	114	17.1%	1.08 [0.60, 1.96]	
Saigusa S 2016	19	45	17	45	8.1%	1.20 [0.52, 2.80]	
Shi SJ 2013	30 19	74 109	34 35	69 153	17.2% 19.8%	0.70 [0.36, 1.36]	
Wang L 2016 zhu H 2015	19	23	26	97	6.8%	0.71 [0.38, 1.33] 0.57 [0.18, 1.85]	
2010 H 2015	4	23	20	97	0.0%	0.57 [0.16, 1.65]	
Total (95% CI)		626		685	100.0%	0.95 [0.73, 1.22]	
Total events	211	020	232			0.00 [0.10, 1.22]	1
Heterogeneity: Chi ² =5		(P=0.49); l ² =0%	,			
Test for overall effect:			,,				0.01 0.1 1 10 1
							Age=<60 Age>60
	Mal		Fema			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Droeser RA 2013	211		217	574	40.1%	0.97 [0.76, 1.23]	
Hamada T 2017	150		234	365	22.8%	0.82 [0.59, 1.15]	
Koganemaru S 2017	12		7	95	2.2%	1.18 [0.45, 3.11]	
Lee LH 2016	5		14	194	4.1%	0.33 [0.12, 0.93]	
Li Y 2016 Liang M 2014	78 52		60 50	110 98	11.3% 5.6%	0.74 [0.46, 1.20]	
Saigusa S 2016	27	64	50 9	96 26	2.2%	1.43 [0.80, 2.56] 1.38 [0.53, 3.56]	
Shi SJ 2013	30		34	82	4.3%	1.37 [0.70, 2.66]	- -
Wang L 2016	37	166	17	96	4.9%	1.33 [0.70, 2.53]	
zhu H 2015	20		10	49	2.5%	1.53 [0.64, 3.64]	+
Total (95% CI)		1776		1689	100.0%	0.97 [0.84, 1.13]	•
Total events	622		652				
Heterogeneity: Chi ² =1	11.68, <i>df=</i> 9) (P=0.2	3); / ² =23	3%			0.01 0.1 1 10 1
Test for overall effect:							Male Female
							Wale Female
	Color		Rectur	m		Odds Ratio	Odds Ratio
Study or Subgroup	Events		Events	Total		M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Hamada T 2017	313	495	70	120	37.3%	1.23 [0.82, 1.84]	- <u> </u> =-
Li Y 2016	64	129	74	147	31.4%	0.97 [0.61, 1.56]	
Shi SJ 2013	58	132	6	11	5.6%	0.65 [0.19, 2.25]	
Wang L 2016	29	141	25	121	19.2%	0.99 [0.55, 1.81]	
zhu H 2015	14	41	16	79	6.5%	2.04 [0.88, 4.76]	
		938		478	100.0%	1.12 [0.87, 1.45]	•
Total (95% CI) Total events	478	330	191	4/0	100.070	1.12 [0.07, 1.45]	ľ
Heterogeneity: Chi ² =:	3 36 df=4	(P=0.5	131 $1^{2}=0^{9}$	6			
Test for overall effect:			0),,, 0,				0.01 0.1 1 10 1
	2 0.00 (/	0.07)					Colon Rectum
	Wel		loderate	/poor			Odds Ratio
Study or Subgroup	Events	Total	Events	Tot	al Weigh	t M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Droeser RA 2013	394	994	29	12	23 22.89	6 2.13 [1.38, 3.29	-
Hamada T 2017	351	563	33		52 16.79		
Koganemaru S 2017	17	217	2		8 2.5%		
Lee LH 2016	1	11	18	37			
Li Y 2016	102	204	28		56 16.19		
Liang M 2014	73 31	125 80	29 5		30 11.9% 10 4.0%		
Saigusa S 2016	27	76	37				
Shi SJ 2013	3	9	51	25			
Wang L 2016 zhu H 2015		18	27	10			
	3					0.00 [0.10, 2.07	
2110 11 2013	3	.0	2.				
Total (95% CI)	3	2297	2.		19 100.0%	6 1.18 [0.94, 1.48	•
Total (95% CI) Total events	1002	2297	259	111	19 100.0%	6 1.18 [0.94, 1.48	•
Total (95% CI)	1002	2297	259	111	19 100.0%	6 1.18 [0.94, 1.48	
Total (95% CI) Total events	1002 20.29, <i>df</i> =9	2297 9 (<i>P</i> =0.0	259	111	19 100.0%	6 1.18 [0.94, 1.48	0.001 0.1 1 10 10
Total (95% CI) Total events Heterogeneity: <i>Chi</i> ² =2	1002 20.29, df=9 Z=1.44 (F	2297 9 (<i>P</i> =0.0 P=0.15)	259 2); / ² =56	111	19 100.0%		0.001 0.1 1 10 10 Well Moderate/poor
Total (95% CI) Total events Heterogeneity: <i>Chi</i> ² =2 Test for overall effect:	1002 20.29, <i>df</i> =9 <i>Z</i> =1.44 (F T1-2	2297 9 (<i>P</i> =0.0 P=0.15)	259 2); / ² =56 T3-4	111 6%		Odds Ratio	0.001 0.1 1 10 10 Well Moderate/poor Odds Ratio
Total (95% CI) Total events Heterogeneity: Chi ² =2 Test for overall effect: Study or Subgroup	1002 20.29, df=9 Z=1.44 (F T1-2 Events	2297 9 (<i>P</i> =0.0 2=0.15) Total	259 2); / ² =56 T3-4 <u>Events</u>	111 6% <u>Total</u>	Weight M	Odds Ratio <u>A-H, Random, 95% C</u>	0.001 0.1 1 0 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Chi ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013	1002 20.29, <i>df=</i> 9 <i>Z</i> =1.44 (<i>F</i> <u>T1-2</u> <u>Events</u> 113	2297 9 (<i>P</i> =0.0 =0.15) Total 239	259 2); / ² =56 T3-4 <u>Events</u> 308	111 6% <u>Total</u> 878	<u>Weight</u> 15.8%	Odds Ratio <u>A-H, Random, 95% C</u> 1.66 [1.24, 2.22	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Chi ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017	1002 20.29, <i>df</i> =9 <i>Z</i> =1.44 (<i>F</i> T1-2 Events 113 0	2297 9 (<i>P</i> =0.0 P=0.15) Total 239 53	259 (2); / ² =56 T3-4 <u>Events</u> 308 19	111 6% <u>Total</u> 878 182	<u>Weight N</u> 15.8% 3.6%	Odds Ratio 1-H. Random, 95% C 1.66 [1.24, 2.22 0.08 [0.00, 1.32	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 .ee LH 2016	1002 20.29, df=5 Z=1.44 (F <u>T1-2</u> Events 113 0 7	2297 9 (<i>P</i> =0.0 2=0.15) Total 239 53 92	259 2); / ² =56 T3-4 <u>Events</u> 308 19 11	111 6% <u>Total</u> 878 182 289	Weight N 15.8% 3.6% 11.5%	Odds Ratio 1-H, Random, 95% C 1.66 [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 Lee LH 2016 LJ 2016	1002 20.29, <i>df</i> =9 <i>Z</i> =1.44 (<i>F</i> T1-2 Events 113 0	2297 9 (<i>P</i> =0.0 P=0.15) Total 239 53	259 2); <i>f</i> ² =56 T3-4 Events 308 19 11 114	111 6% Total 878 182 289 233	Weight M 15.8% 3.6% 11.5% 13.8%	Odds Ratio 1-H. Random, 95% C 1.66 [1.24, 2.22 0.08 [0.00, 1.32	0.001 0.1 10 10 Well Moderate/poor Odds Ratio MH, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 .ee LH 2016	1002 20.29, df=5 Z=1.44 (F <u>T1-2</u> Events 113 0 7 24	2297 9 (<i>P</i> =0.0) 2=0.15) Total 239 53 92 43	259 2); / ² =56 T3-4 <u>Events</u> 308 19 11	111 6% <u>Total</u> 878 182 289	Weight N 15.8% 3.6% 11.5%	Odds Ratio <u>1.66</u> [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch^2 =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 Lee LH 2016 Li Y 2016 Li M 2014	1002 20.29, df=5 Z=1.44 (F <u>T1-2</u> <u>Events</u> 113 0 7 24 23	2297 9 (<i>P</i> =0.0) 2=0.15) Total 239 53 92 43 66	259 2); ² =56 T3-4 <u>Events</u> 308 19 11 114 79	111 6% <u>Total</u> 878 182 289 233 119	Weight N 15.8% 3.6% 11.5% 13.8% 13.9%	Odds Ratio <u>A-H, Random, 95% C</u> 1.66 [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 .ee LH 2016 Li Y 2016 Jaigusa S 2016 Shi SJ 2013 Wang L 2016	1002 20.29, df=5 Z=1.44 (F T1-2 Events 113 0 7 7 24 23 13 5 5 5	2297 9 (<i>P</i> =0.0 P =0.15) Total 239 53 92 43 66 40	259 2); ² =56 T3-4 <u>Events</u> 308 19 11 114 79 23	111 6% 70tal 878 182 289 233 119 50	Weight N 15.8% 3.6% 11.5% 13.8% 13.9% 12.3%	Odds Ratio A-H, Random, 95% C 1.66 [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 2.02 [0.66, 6.18	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Test for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 .ee LH 2016 .iang M 2014 Saigusa S 2016 Shi SJ 2013	1002 20.29, df= Z=1.44 (F Events 113 0 7 24 23 13 5	2297 a (<i>P</i> =0.0 b (<i>P</i> =0.15) b (<i>P</i> =0.15) c (<i>P</i>	259 2); l^2 =56 T3-4 Events 308 19 11 114 79 23 61	111 6% 70tal 878 182 289 233 119 50 128	Weight 1 15.8% 3.6% 11.5% 13.8% 13.9% 12.3% 10.5%	Odds Ratio 1.66 [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch^2 =22 Exector versal effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 eac LH 2016 Lin Y 2016 Ling M 2014 Salgusa S 2016 Shi SJ 2013 Wang L 2016 zhu H 2015	1002 20.29, df=5 Z=1.44 (F T1-2 Events 113 0 7 7 24 23 13 5 5 5	2297 (<i>P</i> =0.0 2 -0.15) Total 239 53 92 43 66 40 15 17	259 (2); / ² =56 T3-4 Events 308 19 11 114 79 23 61 49 28	Total 878 182 289 233 119 50 128 247 103	Weight 1 15.8% 3.6% 11.5% 13.8% 13.9% 12.3% 10.5% 8.0%	Odds Ratio <u>4H, Random, 95% C</u> 0.08 [0.00, 1.32 2.08 [0.78, 554 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 2.02 [0.66, 6.18 0.36 [0.08, 1.66]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogenetity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Cogaremanu S 2017 esc LH 2016 Lang M 2014 Sagusa S 2016 Sh SJ 2013 Wang L 2016 tu H 2015 Total (95% CI)	1002 20.29, df= Z=1.44 (F Events 113 0 7 24 23 13 5 5 2	2297 (<i>P</i> =0.0) 239 53 92 43 66 40 15 15	259 (2); l^2 =56 T3-4 Events 308 19 11 114 79 23 61 49 28	Total 878 182 289 233 119 50 128 247 103	Weight N 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 10.5%	Odds Ratio A-H, Random, 95% C 1.66 [1.24, 2.22 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 2.02 [0.66, 6.18	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch^2 =22 Est for overall effect: Study or Subgroup Toreser RA 2013 Koganemaru S 2017 ce LH 2016 Lin X 2016 Lin X 2013 Mang L 2016 thu H 2015 Total (95% CI) Total events	1002 20.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 4 23 13 5 5 5 2 2 192	2297 (<i>P</i> =0.0 2 -0.15) Total 239 53 92 43 66 40 15 15 17 580	259 (2); f^2 =50 T3-4 Events 308 19 11 114 79 23 61 49 28 692	111 6% 70tal 878 182 289 233 119 50 128 247 103 2229	Weight 1 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0%	Odds Ratio Att, Random, 35% C 1.66 [124, 2.22 0.08 [0.00, 1.32 0.28 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 0.36 [0.08, 1.66 0.81 [0.44, 1.48	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganemaru S 2017 cang M 2014 Sagusa S 2016 Si SJ 2013 Wang L 2016 tu H 2015 Total (95% CI) Total events Heterogenetic; Tau ² =C	1002 20.29, df= Z=1.44 (F Events 113 0 7 24 23 13 5 5 2 2 192 20.58 Chr ² =	2297 (<i>P</i> =0.0) (<i>P</i> =0.15) Total 239 53 92 43 66 40 15 15 17 580 39.09, 0	259 (2); f^2 =50 T3-4 Events 308 19 11 114 79 23 61 49 28 692	111 6% 70tal 878 182 289 233 119 50 128 247 103 2229	Weight 1 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0%	Odds Ratio Att, Random, 35% C 1.66 [124, 2.22 0.08 [0.00, 1.32 0.28 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 0.36 [0.08, 1.66 0.81 [0.44, 1.48	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Ch^2 =22 Est for overall effect: Study or Subgroup Toreser RA 2013 Koganemaru S 2017 ce LH 2016 Lin X 2016 Lin X 2013 Mang L 2016 thu H 2015 Total (95% CI) Total events	1002 20.29, df= Z=1.44 (F Events 113 0 7 24 23 13 5 5 2 2 192 20.58 Chr ² =	2297 (<i>P</i> =0.0) (<i>P</i> =0.15) Total 239 53 92 43 66 40 15 15 17 580 39.09, 0	259 (2); f^2 =50 T3-4 Events 308 19 11 114 79 23 61 49 28 692	111 6% 70tal 878 182 289 233 119 50 128 247 103 2229	Weight 1 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0%	Odds Ratio Att, Random, 35% C 1.66 [124, 2.22 0.08 [0.00, 1.32 0.28 [0.78, 5.54 1.32 [0.69, 2.54 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.55 [0.18, 1.70 0.36 [0.08, 1.66 0.81 [0.44, 1.48	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganemaru S 2017 cang M 2014 Sagusa S 2016 Si SJ 2013 Wang L 2016 tu H 2015 Total (95% CI) Total events Heterogenetic; Tau ² =C	1002 20.29, df=5 Z=1.44 (F T1-2 Events 113 0 7 24 23 13 5 5 2 192 2.58 Ch ² = Z=0.69 (F	2297 (<i>P</i> =0.0) (<i>P</i> =0.15) Total 239 53 92 43 66 40 15 15 17 580 39.09, 0	259 2); l^2 =56 T3-4 Events 308 19 11 114 79 23 61 49 28 61 49 28 61 49 28	111 6% 70tal 878 182 289 233 119 50 128 247 103 2229	Weight 1 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0%	Odds Ratio 1.66 (1.24, 22, 22, 00, 13, 25, 20, 20, 20, 20, 20, 20, 20, 20, 23, 254, 13, 20, 059, 254, 13, 20, 059, 254, 13, 20, 059, 254, 10, 20, 10, 20, 10, 20, 10, 20, 20, 20, 20, 20, 20, 20, 20, 20, 2	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Chr ² =2 Test for overall effect: Study or Subgroup Dreser RA 2013 Koganemaru S 2017 Lang M 2014 Salguas S 2016 Shi SJ 2013 Mang L 2016 zhu H 2015 Total (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneity: Tau ² =C	1002 20.29, df=5 Z=1.44 (F T1-2 Events 0 7 24 23 13 5 5 2 2 192 2.58 <i>Chi²</i> = Z=0.69 (F N0	2297 (<i>P</i> =0.15) Total 239 53 92 43 66 40 15 17 580 39.09, (≥=0.49)	259 2); $l^2 = 56$ T3-4 Events 308 19 11 114 79 23 61 49 28 692 28 692 <i>If=</i> 8 (<i>P</i> < N1-2	111 5% Total 878 182 289 233 119 50 128 247 103 2229 0.0000	Weight In 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 10.5% 100.0% 11); P=809	Odds Ratio AtH, Random, 95%, C 41, Random, 95%, C 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 20, 100, 100, 100, 100, 100, 100, 10	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganemaru S 2017 cang M 2014 Sagusa S 2016 Si SJ 2013 Wang L 2016 tu H 2015 Total (95% CI) Total events Heterogenetic; Tau ² =C	1002 20.29, df=5 Z=1.44 (F T1-2 Events 0 7 24 23 13 5 5 2 2 192 2.58 <i>Chi²</i> = Z=0.69 (F N0	2297 (<i>P</i> =0.15) Total 239 53 92 43 66 40 15 17 580 39.09, (≥=0.49)	259 2); <i>f</i> ² =56 T3-4 Events 308 19 11 114 79 23 61 49 28 692 <i>ff=8</i> (<i>P</i> < N1-2 vents	111 5% Total 878 182 289 233 119 50 128 247 103 2229 0.0000 Total	Weight In 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 10.5% 100.0% 11); P=809	Odds Ratio 1.66 (1.24, 222) 0.08 (0.00, 1.32 2.08 (0.78, 554 1.32 (0.69, 2.54 0.57 (0.24, 0.55 0.57 (0.24, 0.55 0.56 (0.8, 1.66 0.36 (0.08, 1.66 0.31 (0.44, 1.48 6 Odds Ratio H, Random, 95% Cl	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl
Total (95% C1) Total events Heterogenetic: Ch [#] =2 Tereser RA 2013 Orgeser RA 2013 Cogganemaru S 2017 Lang M 2014 Lang M 2014 Lang M 2014 Lang M 2014 Saguss 3 2016 this J 2013 Nang L 2016 this J 2013 Total (95% C1) Total events Heterogenetic: Tau ² =C fest for overall effect: Study or Subgroup	1002 20.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 23 13 5 5 5 2 2 0.58 Ch/ ² = Z=0.69 (F N0 Events	2297 (P=0.0.5) Total 239 53 92 43 66 40 15 15 17 580 39.09, (39.09, (39.09, (20, 49) Total E	259 2); <i>f</i> ² =56 T3-4 Events 308 11 114 79 23 61 49 28 692 28 692 #=8 (<i>P</i> <	111 5% Total 878 182 289 50 128 247 103 2229 0.00000 Total 530	Weight N 15.8% 3.6% 11.5% 3.8% 13.8% 13.9% 10.5% 8.0% 100.0% 1); f²=80% Weight M	Odds Ratio AtH, Random, 95%, C 41, Random, 95%, C 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 80, 100, 1, 32, 20, 20, 100, 100, 100, 100, 100, 100, 10	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Idetrogeneity: Ch [#] =2 Test for overall effect: Toreser RA 2013 Xoganemaru S 2017 Lea LH 2016 Laing M 2014 Salugus S 2016 Shi SJ 2013 Wang L 2016 John J 2015 Total (95% CI) Total events Telest for overall effect: Study or Subgroup Drosest RA 2013	1002 20.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 23 13 5 5 2 2 192 0.58 Ch ² = Z=0.69 (F N0 Events 233	2297 (P=0.C) (P=0.C	2599 2); <i>P</i> ² =5t6 T3-4 Events 308 19 11 114 79 23 61 49 28 692 28 692 28 692 <i>ef=8 (P<</i> N1-2 1 81	111 5% <u>Total</u> 878 182 289 233 119 50 128 247 103 2229 0.0000 0 <u>Total</u> 1530 185	Weight M 15.8% 3.6% 11.5% 13.8% 13.9% 12.3% 10.5% 8.0% 100.0% (1); f ² =80? Weight M 15.8%	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 554 0.27 [0.47, 055] 0.57 [0.24, 1.34 0.55 [0.18, 1.70 2.02 [0.66, 6.18] 0.36 [0.08, 1.66 0.81 [0.44, 1.48 6 Odds Ratio H, Random, 95% C] 0.99 [0.38, 2.55]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% C1) Total events Heterogenetic: Ch ² =2 Terest for overall effect: Study or Suboroup Dresser RA 2013 Coganemaru S 2017 Liang M 2014 Liang M 2014 Liang M 2014 Study or Suboroup Total (95% C1) Total events Heterogenetic: Tau ² =C Fest for overall effect: Study or Suboroup Dresser RA 2013 Dresser RA 2016 Liny 2016 Liang M 2014	1002 20.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 13 3 3 3 3 13 5 5 5 2 192 2 0.58 Ch ² = Z=0.69 (F No Events 2 3 3 9	2297 ⇒0.(P=0.0.15) ⇒0.15) 2399 53 92 239 53 92 43 66 66 40 15 15 17 580 39.09, (39.09, (43) 53 53 92 53 53 53 55 57 55 57 55 55 55 55 55 55	259 2); P^2 =5(T3-4 Events 308 19 11 114 79 23 61 49 28 692 28 692 28 692 28 692 28 N1-2 181 9	111 5% 70 70 70 70 70 70 70 70 70 70 70 70 70	Weight 1 15.8% 3.6% 13.9% 13.9% 12.3% 10.5% 8.0% 100.0% 11); ℓ ² =80% Weight M 15.8% 10.1% 14.2%	Odds Ratio Atl, Random, 95%, C 1.66 (1.24, 2.22 0.08 (0.00, 1.32 0.08 (0.78, 5.54 1.32 (0.69, 2.54 0.27 (0.17, 0.51 0.57 (0.24, 1.34 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H, Random, 95%, C(1.34 (1.05, 1.71)	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events releterogeneity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganemau S 2017 eu LH 2016 Lang M 2014 Saiguss S 2016 Study L2016 tru H 2015 Total events reletorgeneity: Tau ² =C Total (95% CI) Total events reletorgeneity: Tau ² =C Total Official (95% CI) Total events reletorgeneity: Tau ² =C Total Official (95% CI) Total events reletorgeneity: Tau ² =C Total 2016 Li 2	1002 220.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 4 23 13 5 5 2 2 192 0.58 Ch/ ² = Z=0.68 Ch/ ² Z=0.90 (F Z-233 9 9 63 63 26 21	2297 ∂ (P=0.C =0.15) 7 7 7 7 7 7 7 7 7 7 7 7	259 2); / ² =5(Events 3008 19 11 11 49 28 61 49 28 692 28 692 28 692 4/f=8 (/P< N1-2 181 9 75 76 15	111 5% Total 878 182 289 233 119 5247 103 2229 0.00000 128 247 103 2229 0.00000 530 185 156 185 156 108 31	Weight II 15.8% 3.6% 13.8% 13.9% 12.3% 10.5% 8.0% 100.0% 11); P²=80? Weight II 15.8% 10.1% 12.2% 12.9% 10.6%	Odds Ratio 41, Random, 95% C 1,66 (1 24, 2, 22 0,08 (0,0, 1, 22 0,08 (0,0, 1, 22 0,08 (0,0, 1, 25 1,32 (0,69, 24 0,27 (0,17, 0,51 0,57 (0,24, 1,34 0,36 (0,08, 1,66 0,81 (0,04, 1,48 6 Odds Ratio 1,34 (1,05, 1,71) 0,99 (0,38, 25) 1,19 (0,74, 1,52) 0,21 (0,11,0,40 1,19 (0,74,1,52) 0,21 (0,11,0,40) 1,19 (0,74,1,52) 0,21 (0,11,0,40) 1,19 (0,74,1,52) 0,21 (0,11,0,40) 1,20 (0,21,1,52) 0,21 (0,11,0,40) 1,20 (0,21,1,52) 0,21 (0,11,0,40) 1,20 (0,21,1,52) 1,20 (0,21,1,52) 1,20 (0,21,1,52) 1,20 (0,11,0,40) 1,20 (0,21,1,52) 1,20 (0,21,1,52)	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Heterogeneity: Ch ² =22 Est for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 Lang M 2014 Salguss S 2016 Shi SJ 2013 Shi SJ 2013 Nang L 2016 Heterogeneity: Tau ² =C Total (95% CI) Total events Total events Study or Subgroup Droeser RA 2015 Lang M 2016 Lang M 2014 Salguss S 2016 Lang M 2014 Salguss S 2016	1002 20.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 23 13 5 5 2 192 2.58 Ch ² = Z=0.69 (F N0 Events 23 3 3 3 6 3 6 3 2	2297 ∂ (P=0.15) Total 239 92 43 92 43 66 40 15 17 580 39.09, (39.09, (39.09, (40, 15) 17 580 39.09, (17 580 17 580 17 580 17 580 18 17 580 18 17 580 18 17 580 18 18 17 580 18 18 17 580 18 18 18 18 18 18 18 18 18 18	259 2); $r^2=5t$ 308 19 11 114 114 79 23 61 28 692 28 692 28 692 28 692 28 692 28 75 75 76	111 5% Total 878 182 289 233 119 5247 103 2229 0.00000 128 247 103 2229 0.00000 530 185 156 185 156 108 31	Weight 1 15.8% 3.6% 13.9% 13.9% 12.3% 10.5% 8.0% 100.0% 11); ℓ ² =80% Weight M 15.8% 10.1% 14.2%	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 554 0.27 [0.77, 057] 0.57 [0.24, 1.34 0.57 [0.24, 1.34 0.57 [0.24, 1.34 0.36 [0.08, 1.66 0.81 [0.44, 1.48 6 Odds Ratio H, Random, 95% CI 1.34 [10.5, 1.7] 0.99 [0.38, 2.55] 1.9 [0.74, 1.32] 0.99 [0.38, 2.55] 1.9 [0.74, 1.32] 0.99 [0.38, 2.55] 1.9 [0.74, 1.32] 0.21 [0.11, 0.40]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events reletengenetity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganeman 3 2017 ee LH 2016 Lang M 2014 Saigusa 5 2016 Sh SJ 2013 Vang L 2016 total (95% CI) Total events reletengenetiv: Tau ² =C Test for overall effect: Study or Subgroup Droeser RA 2013 ee LH 2016 Lang M 2014 Saigusa 5 2016 Sh SJ 2013 Mang L 2016	1002 20.29, df= Z=1.44 (f) T1-2 Events 113 0 7 24 23 13 5 5 2 2 0.58 Ch ² = Z=0.69 (f) N0 Events 233 9 63 26 21 33 27	2297 (P=0.0 (P=0.0 Total 239 239 239 43 66 40 15 15 15 15 17 580 39.09, (, 43 66 83.09, (, 43 15 15 17 580 39.09, (, 43 15 15 17 580 187 197 580 187 187 187 187 187 187 187 187	259 2); f^2 =50 T3-4 308 19 111 49 28 612 49 28 692 28 692 28 692 49 692 56 692 57 6 76 76 15 76 15 31 27	111 5% 701 182 289 233 119 500 128 247 103 2229 0.00000 701 150 155 156 108 31 156 108 31 71 124	Weight № 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0% 11); P=809 Weight № 15.8% 10.1% 12.9% 12.6% 12.6%	Odds Ratio 41, Random, 95% C 1, 66 (1 24, 2 22 0.08 (0.01, 132 2.08 (0.78, 554 1.32 (0.69, 254 0.27 (0.17, 0.51 0.57 (0.24, 134 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H. Random, 95% Cf 1.34 (1.05, 171) 0.99 (0.38, 2.55) 1.19 (0.74, 1.52) 0.24 (1.43, 1.59) 0.25 (0.24, 1.43) 1.08 (0.56, 2.11) 0.56 (0.24, 1.43) 1.087 (0.48, 1.59)	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Heterogeneity: Ch ² =22 Est for overall effect: Study or Subgroup Droeser RA 2013 Koganemaru S 2017 Lang M 2014 Salguss S 2016 Shi SJ 2013 Shi SJ 2013 Nang L 2016 Heterogeneity: Tau ² =C Total (95% CI) Total events Total events Study or Subgroup Droeser RA 2015 Lang M 2016 Lang M 2014 Salguss S 2016 Lang M 2014 Salguss S 2016	1002 220.29, df= Z=1.44 (F T1-2 Events 113 0 7 24 23 5 5 2 2 192 2.58 Ch ² = Z=0.69 (F N0 Events 233 9 6 3 26 21 33	2297 ∂ (P=0.0 =0.15) 7 7 7 7 7 7 7 7 7 7 7 239 53 92 43 39 239 43 39 24 40 15 15 15 15 15 15 15 15 15 15	259 2); <i>P</i> =56 T3-4 308 19 11 114 79 23 61 49 28 692 28 692 28 692 28 N1-2 181 181 75 76 15 31	111 5% 701 182 289 233 119 500 128 247 103 2229 0.00000 701 150 155 156 108 31 156 108 31 71 124	Weight I 15.8% 3.6% 11.5% 13.8% 12.3% 10.5% 8.0% 100.0% 11); P=809 Weight M 15.8% 10.1% 14.2% 12.9% 10.6%	Odds Ratio Att, Random, 35% C 1.66 [124, 222 0.08 [0.00, 1.32 0.08 [0.07, 8, 554 1.32 [0.99, 254 0.27 [0.17, 0.51 0.57 [0.24, 1.34 0.36 [0.08, 1.66 0.81 [0.44, 1.48 6 Odds Ratio 1.34 [105, 1.71] 0.99 [0.38, 255] 1.19 [0.74, 1.52] 0.21 [0.11, 0.40] 0.55 [0.24, 1.43] 0.21 [0.11, 0.40] 0.56 [0.24, 1.43] 0.21 [0.11, 0.40] 0.56 [0.24, 1.43] 0.56 [0.24, 1.43] 0.55 [0.24, 1.54] 0.55 [0.24, 1.5	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events reletengenetity: Ch ² =2 Test for overall effect: Study or Subgroup Droeser RA 2013 Coganeman 3 2017 ee LH 2016 Lang M 2014 Saigusa S 2016 Sh SJ 2013 Vang L 2016 total (95% CI) Total events reletengenetiv: Tau ² =C Total (95% CI) Total events reletengenetiv: Tau ² =C Total (95% CI) Total 2016 Lang M 2014 Saigusa S 2016 Sh SJ 2013 Saigusa S 2016 Sh SJ 2013 Sh SJ 2013 Sh SJ 2013 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh SJ 2016 Sh SJ 2013 Sh SJ 2016 Sh	1002 20.29, dr= 2 Z =1.44 (<i>F</i> Events 113 10 0 7 24 23 3 5 5 5 2 2 9 9 5.8 Ch ² = 9 20.58 Ch ² = 9 20.58 Ch ² = 9 20.58 Ch ² = 10 2 20.58 Ch ² = 10 2 2 3 3 2 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	2297 () (P=0.0.)=0.15) 7 239 53 92 43 66 40 15 15 15 580 (39.09, (39.09, (39.09, (39.09, (120) 77 59 120 72 138 68	259 2); <i>P</i> =56 308 19 11 114 49 28 692 <i>ff</i> =8 (<i>P</i> < N12 76 5 31 27 20	111 5% 5% 182 289 233 119 50 128 247 103 2229 0.00000 185 156 108 31 71 124 52	Weight 1, 1 15.8% 3.6% 11.5% 13.8% 13.8% 13.8% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5%	Odds Ratio 41, Random, 95% C 1, 66 (1 24, 2.22 0.08 (0.00, 1.32 0.08 (0.78, 554 1.32 (0.89, 254 0.27 (0.17, 0.51 0.57 (0.24, 1.34 0.36 (0.08, 1.66 0.81 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H: Random, 95% Cf 1.34 (1.05, 1.71) 0.99 (0.38, 255) 1.19 (0.74, 1.82) 0.21 (0.11, 0.49) 0.58 (0.24, 1.43) 1.09 (0.56, 2.11) 0.59 (0.24, 1.43) 1.087 (0.48, 1.59) 0.28 (0.12, 0.66)	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Hederogeneity: Chr ² =2 Test for overall effect: Toreser RA 2013 Xoganemaru S 2017 Lang M 2014 Salugus S 2016 Lang M 2014 Salugus S 2016 Shi SJ 2013 Wang L 2016 Lang M 2014 Salugus S 2016 Shi SJ 2013 Yong L 2016 Chail events Total (95% CI) Total events Study or Subgroup Y 2016 Lang M 2014 Saligusa S 2016 Shi SJ 2013 Yoneser RA 2013 cee LH 2016 L'Y 2016 Ling M 2014 Saligusa S 2016 Shi SJ 2013 Wang L 2016 Ling M 2014 Saligusa S 2016 Shi SJ 2013 Total (95% CI)	1002 20.29, df=i Zz=1.44 (<i>f</i> 113 113 13 13 13 13 13 13 13 13 13 13 1	2297 (P=0.0 (P=0.0 Total 239 239 239 43 66 40 15 15 15 15 17 580 39.09, (, 43 66 83.09, (, 43 15 15 17 580 39.09, (, 43 15 15 17 580 187 197 580 187 187 187 187 187 187 187 187	259 T3-4 Events 308 19 11 114 79 23 61 4 79 28 692 28 N1-2 75 692 181 181 9 75 76 15 31 27 20 1	111 5% 701 182 289 233 119 500 128 247 103 2229 0.00000 701 150 155 156 108 31 156 108 31 71 124	Weight 1, 1 15.8% 3.6% 11.5% 13.8% 13.8% 13.8% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5%	Odds Ratio 41, Random, 95% C 1, 66 (1 24, 2 22 0.08 (0.01, 132 2.08 (0.78, 554 1.32 (0.69, 254 0.27 (0.17, 0.51 0.57 (0.24, 134 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H. Random, 95% Cf 1.34 (1.05, 171) 0.99 (0.38, 2.55) 1.19 (0.74, 1.52) 0.24 (1.43, 1.59) 0.25 (0.24, 1.43) 1.08 (0.56, 2.11) 0.56 (0.24, 1.43) 1.087 (0.48, 1.59)	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Heterogenetic; Chi ⁺ =2 Test for overall effect: Study or Suboroup Droeser RA 2013 Cogaremanu S 2017 ee LH 2016 Lang M 2014 Saiguss S 2016 Sh SJ 2013 Nang L 2016 total (95% CI) Total events Heterogenetic; Tau ² =C Total (95% CI) Total events Subdy or Suboroup Droeser RA 2013 Lang M 2014 Lang M	1002 20.29, dt= Z≥1.44 (F Tr1-2 Events 113 3 5 5 5 2 2 192 2 5.88 Ch ² (F NO Events 2 233 3 3 2 7 10 10 2 11 2 11 2 11 2 11 2 11 3 11 3 1	2297 (P=0.0) (P=0.15)	259 259 308 19 11 114 79 23 61 49 28 692 28 692 26 8 692 15 8 16 9 75 76 15 31 27 20 21	111 5% Total 878 182 289 50 128 247 103 2229 0.00000 Total 150 185 156 108 31 71 122 100000 185 156 108 31 71 52 1257	Weight 1, 1 15.8% 3.6% 11.5% 13.3% 10.5% 12.3% 8.0% 00.0% Weight M. 15.8% Weight M. 15.8% 10.1% 10.1% 10.1% 10.5% 00.0%	Odds Ratio 41, Random, 95% C 166 [124, 222 0.08 [000, 132 0.08 [000, 132 0.08 [000, 132 0.07 [0.17, 0.51 0.57 [0.24, 134 0.55 [0.18, 1.70 0.20 [0.66, 6.186 0.81 [0.44, 1.48 6 Odds Ratio 1.34 (1.05, 171) 0.99 [0.38, 2.55] 1.19 [0.74, 1.92] 0.27 [0.11, 0.40] 0.55 [0.24, 1.33] 1.09 [0.56, 2.11] 0.55 [0.24, 1.43] 1.08 [0.56, 2.11] 0.57 [0.24, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio
Total (95% CI) Total events Idetrogeneity: Ch ²⁺ ≡2 Test for overall effect: Toreser RA 2013 Xoganemaru S 2017 Lang M 2014 Salugus S 2016 Lang M 2014 Salugus S 2016 Shub X 2013 Wang L 2016 Total (95% CI) Total events Test for overall effect: Study or Subgroup Droseer RA 2013 Lee KI 2016 Ling M 2014 Salguas S 2016 Shi SJ 2013 Mang L 2016 Ling M 2014 Salguas S 2016 Shi SJ 2013 Mang L 2016 chu H 2015 Total (95% CI) Total (95% CI) <tr< td=""><td>$\begin{array}{c} 1002\\ 202-144 \ (\ell\\ \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$</td><td>2297 (P=0.15) ¹Total 239 53 92 43 66 40 15 17 580 39.09, (39.09, (39.09, (120 77 59 128 187 120 77 138 68 128 128 128 128 128 128 128 12</td><td>259 259 308 19 11 114 79 23 61 49 28 692 28 692 26 8 692 15 8 16 9 75 76 15 31 27 20 21</td><td>111 5% Total 878 182 289 50 128 247 103 2229 0.00000 Total 150 185 156 108 31 71 122 100000 185 156 108 31 71 52 1257</td><td>Weight 1, 1 15.8% 3.6% 11.5% 13.3% 10.5% 12.3% 8.0% 00.0% Weight M. 15.8% Weight M. 15.8% 10.1% 10.1% 10.1% 10.5% 00.0%</td><td>Odds Ratio 41, Random, 95% C 166 [124, 222 0.08 [000, 132 0.08 [000, 132 0.08 [000, 132 0.07 [0.17, 0.51 0.57 [0.24, 134 0.55 [0.18, 1.70 0.20 [0.66, 6.186 0.81 [0.44, 1.48 6 Odds Ratio 1.34 (1.05, 171) 0.99 [0.38, 2.55] 1.19 [0.74, 1.92] 0.27 [0.11, 0.40] 0.55 [0.24, 1.33] 1.09 [0.56, 2.11] 0.55 [0.24, 1.43] 1.08 [0.56, 2.11] 0.57 [0.24, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17]</td><td>0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio M-H, Random, 95% Cl</td></tr<>	$\begin{array}{c} 1002\\ 202-144 \ (\ell\\ \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	2297 (P=0.15) ¹ Total 239 53 92 43 66 40 15 17 580 39.09, (39.09, (39.09, (120 77 59 128 187 120 77 138 68 128 128 128 128 128 128 128 12	259 259 308 19 11 114 79 23 61 49 28 692 28 692 26 8 692 15 8 16 9 75 76 15 31 27 20 21	111 5% Total 878 182 289 50 128 247 103 2229 0.00000 Total 150 185 156 108 31 71 122 100000 185 156 108 31 71 52 1257	Weight 1, 1 15.8% 3.6% 11.5% 13.3% 10.5% 12.3% 8.0% 00.0% Weight M. 15.8% Weight M. 15.8% 10.1% 10.1% 10.1% 10.5% 00.0%	Odds Ratio 41, Random, 95% C 166 [124, 222 0.08 [000, 132 0.08 [000, 132 0.08 [000, 132 0.07 [0.17, 0.51 0.57 [0.24, 134 0.55 [0.18, 1.70 0.20 [0.66, 6.186 0.81 [0.44, 1.48 6 Odds Ratio 1.34 (1.05, 171) 0.99 [0.38, 2.55] 1.19 [0.74, 1.92] 0.27 [0.11, 0.40] 0.55 [0.24, 1.33] 1.09 [0.56, 2.11] 0.55 [0.24, 1.43] 1.08 [0.56, 2.11] 0.57 [0.24, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogenetic; Chi ⁺ =2 Test for overall effect: Study or Suboroup Droeser RA 2013 Cogaremanu S 2017 ee LH 2016 Lang M 2014 Saiguss S 2016 Sh SJ 2013 Nang L 2016 total (95% CI) Total events Heterogenetic; Tau ² =C Total (95% CI) Total events Subdy or Suboroup Droeser RA 2013 Lang M 2014 Lang M	$\begin{array}{c} 1002\\ 202-144 \ (\ell\\ \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	2297 (P=0.15) ¹ Total 239 53 92 43 66 40 15 17 580 39.09, (39.09, (39.09, (120 77 59 128 187 120 77 138 68 128 128 128 128 128 128 128 12	259 259 308 19 11 114 79 23 61 49 28 692 28 692 26 8 692 15 8 16 9 75 76 15 31 27 20 21	111 5% Total 878 182 289 50 128 247 103 2229 0.00000 Total 150 185 156 108 31 71 122 100000 185 156 108 31 71 52 1257	Weight 1, 1 15.8% 3.6% 11.5% 13.3% 10.5% 12.3% 8.0% 00.0% Weight M. 15.8% Weight M. 15.8% 10.1% 10.1% 10.1% 10.5% 00.0%	Odds Ratio 41, Random, 95% C 166 [124, 222 0.08 [000, 132 0.08 [000, 132 0.08 [000, 132 0.07 [0.17, 0.51 0.57 [0.24, 134 0.55 [0.18, 1.70 0.20 [0.66, 6.186 0.81 [0.44, 1.48 6 Odds Ratio 1.34 (1.05, 171) 0.99 [0.38, 2.55] 1.19 [0.74, 1.92] 0.27 [0.11, 0.40] 0.55 [0.24, 1.33] 1.09 [0.56, 2.11] 0.55 [0.24, 1.43] 1.08 [0.56, 2.11] 0.57 [0.24, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Indercognanity: Chr ² =2 Test for overall effect: Test for overall effect: Study or Subgroup Droeser RA 2013 Xoganemaru S 2017 Lang M 2014 Salugus S 2016 Sin SJ 2013 Wang L 2016 chu H 2015 Total (95% CI) Total events Total events Test for overall effect: Study or Subgroup Toreser RA 2013 ce LH 2016 Li Y 2016 Liang M 2014 Salguas S 2016 Shi J 2013 Shi J 2013 Vang L 2016 Li Y 2016 Li Z 2016 totu H 2015 Total (95% CI) Total events Telerogenetix: Tau ² =CI Total (95% CI) Total events Telerogenetix: Tau ² =CI Total events Total events Total events Telerogenetix: Tau ² =CI Total events <td>1002 20.29, df=i Z=1.44 (<i>f</i> 113 113 13 13 5 5 2 2 13 13 13 5 5 2 2 192 192 192 192 192 192 192 192 192</td> <td>2297 (<i>P</i>=0.15) (<i>T</i>otal) 239 239 239 43 66 64 40 15 15 580 39.09, (39.09, (40 588 187 187 120 77 72 138 68 188 188 39.09, (249) 77 568 568 568 568 568 568 568 568</td> <td>259 259 73-4 308 19 11 11 14 49 28 692 49 28 692 49 28 692 49 75 61 181 9 75 75 75 72 20 11 15 31 127 20</td> <td>111 5% Total 878 182 289 233 119 50 128 247 103 2229 0.0000 Total 153 156 108 31 157 155 165 124 527 1 0.0000 Total 150 150 150 155 155 155 155 155</td> <td>Weight 1, 15.8% 3.6% 11.5% 13.8% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 10.5% 10.5% 10.5% 10.5% 10.5% 0.0% 11.7° 10.5%</td> <td>Odds Ratio Atl, Random, 95% C 1.66 (1.24, 2.22 0.08 (0.00, 1.32 0.08 (0.78, 5.54 1.32 (0.69, 2.54 0.27 (0.17, 0.51 0.57 (0.24, 1.34 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H, Random, 95% CC 1.34 (1.05, 1.71) 0.59 (0.24, 1.43) 1.34 (1.05, 1.71) 0.59 (0.24, 1.43) 1.39 (0.65, 1.71) 0.59 (0.24, 1.43) 1.09 (0.66, 2.11) 0.72 (0.44, 1.17) 0.72 (0.44, 1.17) 6</td> <td>0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 M-H, Random, 95% Cl 0.001 0.1 10 10 M-H, Random, 95% Cl 0.01 0.1 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 10 10 10 10 10 1</td>	1002 20.29, df=i Z=1.44 (<i>f</i> 113 113 13 13 5 5 2 2 13 13 13 5 5 2 2 192 192 192 192 192 192 192 192 192	2297 (<i>P</i> =0.15) (<i>T</i> otal) 239 239 239 43 66 64 40 15 15 580 39.09, (39.09, (40 588 187 187 120 77 72 138 68 188 188 39.09, (249) 77 568 568 568 568 568 568 568 568	259 259 73-4 308 19 11 11 14 49 28 692 49 28 692 49 28 692 49 75 61 181 9 75 75 75 72 20 11 15 31 127 20	111 5% Total 878 182 289 233 119 50 128 247 103 2229 0.0000 Total 153 156 108 31 157 155 165 124 527 1 0.0000 Total 150 150 150 155 155 155 155 155	Weight 1, 15.8% 3.6% 11.5% 13.8% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 8.0% 10.5% 10.5% 10.5% 10.5% 10.5% 10.5% 0.0% 11.7° 10.5%	Odds Ratio Atl, Random, 95% C 1.66 (1.24, 2.22 0.08 (0.00, 1.32 0.08 (0.78, 5.54 1.32 (0.69, 2.54 0.27 (0.17, 0.51 0.57 (0.24, 1.34 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H, Random, 95% CC 1.34 (1.05, 1.71) 0.59 (0.24, 1.43) 1.34 (1.05, 1.71) 0.59 (0.24, 1.43) 1.39 (0.65, 1.71) 0.59 (0.24, 1.43) 1.09 (0.66, 2.11) 0.72 (0.44, 1.17) 0.72 (0.44, 1.17) 6	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 M-H, Random, 95% Cl 0.001 0.1 10 10 M-H, Random, 95% Cl 0.01 0.1 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 10 0.01 10 10 10 10 0.01 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 10 10 0.01 10 10 10 10 10 10 10 10 10 10 10 10 1
Total (95% C1) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Suboroup Droeser RA 2013 Cogareman S 2017 Events Suboroup Droeser RA 2013 Study or Suboroup Total (95% C1) Total events Heterogenetic; Tau ² =C Total (95% C1) Total events Suboroup Droeser RA 2013 Suboroup Droeser RA 2013 Suboroup Droeser RA 2013 Suboroup Droeser RA 2013 Suboroup Droeser RA 2013 Suboroup Total (95% C1) Total events H 2016 Sin SJ 2013 Suboroup Droeser RA 2013 Suboroup D	$\begin{array}{c} 1002\\ 202-144 \ (\ell\\ \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	2297 (<i>P</i> =0.15) (<i>T</i> otal) 239 239 239 43 66 64 40 15 15 580 39.09, (39.09, (40 588 187 187 120 77 72 138 68 188 188 39.09, (249) 77 568 568 568 568 568 568 568 568	259 259 308 19 11 114 49 28 60 28 692 26 80 28 692 15 80 27 80 28 11 114 9 75 76 15 31 27 20 20 21 21 21 21 21 21 21 21 21 21 21 21 21	Total 878 182 289 233 111 50 128 50 128 247 103 2229 0.00000 Total 1 530 156 108 31 71 103 2229 0.00000 0.00000 0.00000 R-deficit R-deficit	Weight I 15.9% 15.9% 3.6% 11.5% 13.8% 13.8% 8.0% 10.5% 8.0% 10.5% 10.5% 10.5% 10.5% 10.5% 10.5% 10.5% 10.7% 00.0% 11.7% 00.0% 11.7% 00.0% 11.7%	Odds Ratio 41, Random, 95% C 166 [124, 222 0.08 [000, 132 0.08 [000, 132 0.08 [000, 132 0.07 [0.17, 0.51 0.57 [0.24, 134 0.55 [0.18, 1.70 0.20 [0.66, 6.186 0.81 [0.44, 1.48 6 Odds Ratio 1.34 (1.05, 171) 0.99 [0.38, 2.55] 1.19 [0.74, 1.92] 0.27 [0.11, 0.40] 0.55 [0.24, 1.33] 1.09 [0.56, 2.11] 0.55 [0.24, 1.43] 1.08 [0.56, 2.11] 0.57 [0.24, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17]	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 0.001 0.1 10 10 0.001 0.1 10 10 0.01 0.1 10 10 0.01 0.1 0.1 00 10 0.00 10 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total (95% CI) Total events Heterogenetic; Ch [#] =2 Test for overall effect: Study or Subgroup Toreser RA 2013 Koganemaru S 2017 ee LH 2016 Lang M 2014 Saiguss S 2016 Sh SJ 2013 Nang L 2016 total (95% CI) Total events Heterogenetic; Tau ² =C Test for overall effect: Study or Subgroup Drosser RA 2013 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2014 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2016 Lang M 2017 M 2016 Lang M 2017 M 2016 Lang M 2016 Lang M 2017 M 2016 Lang M 2016 L	1002 2029 df=1 Events 113 0 7 24 4 23 3 5 5 2 2 0.58 <i>Ch²</i> =2 0.58 <i>Ch²</i> =2 2 0.58 <i>Ch²</i> =2 0.58 <i>Ch²</i> =2 10 2 3 3 3 2 6 6 2 11 3 3 3 2 2 3 3 2 3 2 3 3 2 5 5 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 2 2 3 3 3 3 3 2 2 3	2297 239 53 92 43 66 40 15 15 15 15 15 568 187 77 59 568 187 77 59 239 72 138 68 120 77 120 72 138 68 120 72 138 68 120 72 138 68 120 72 138 68 120 72 138 68 120 72 120 120 120 120 120 120 120 12	259 22); $l^2=5t$ 308 19 11 11 11 79 28 692 28 692 28 692 28 692 28 692 28 692 28 692 28 692 20 81 11 11 11 11 11 11 11 11 11 11 11 11	Total 878 878 182 289 233 119 50 128 247 103 2229 0.00000 185 156 108 31 71 124 530 185 166 108 31 71 124 52 1257 0.00000 R-deficid	Weight I 15.8% 15.8% 3.6% 11.5% 13.8% 13.8% 13.8% 13.8% 8.0% 10.5% 8.0% 10.5% 10.5% 10.5% 10.5% 10.5% 10.7% 00.0% 11.7% 00.0% 11.7% 00.0% 11.7% 00.0% 11.7%	Odds Ratio H, Random, 95% C 14, Random, 95% C 132 (0.69, 224 1.32 (0.69, 224 1.32 (0.69, 224 1.32 (0.69, 224 0.27 (0.17, 0.51 0.57 (0.24, 1.34 0.35 (0.18, 1.70 2.02 (0.66, 6.18 0.36 (0.08, 1.66 0.81 (0.44, 1.48 6 Odds Ratio H, Random, 95% C 0.24 (1.43, 1.59) 0.25 (0.24, 1.43) 1.99 (0.56, 2.11) 0.55 (0.24, 1.43) 1.99 (0.56, 2.11) 0.55 (0.24, 1.43) 1.08 (1.05, 1.71) 6 Odds Ratio H, Random, 95% 1.69 (1.12, 2.16) 0.72 (0.44, 1.17) 6	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% CI 0.001 0.1 10 10 0.001 0.1 10 10 0.001 0.1 10 10 0.01 0.1 10 10 M-H, Random, 95% CI 0.01 0.1 10 10 M-H, Random, 95% CI
Total (95% CI) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Suboroup Drosser RA 2013 Coganemaru S 2017 Ling M 2014 Ling M 2014 Ling M 2014 Ling M 2016 Ling M 2016 Ling M 2016 Ling M 2016 Ling M 2016 Total events Heterogenetic; Tau ² =C Total (95% CI) Total events Heterogenetic; Tau ² =C Total Suboroup Drosser RA 2013 Situ H 2015 Total (95% CI) Total events Heterogenetic; Tau ² =C Total 2017 Heterogenetic; Tau ² =C Heterogenetic; Tau ² =C Heterogene	1002 20.29, df=1 27-1.44 (<i>f</i> 113 113 13 13 5 5 5 2 2 13 13 13 5 5 5 2 2 13 13 13 13 5 5 5 2 2 10 2 10 2 10 5 8 (<i>h</i>)=1 4 2 2 13 3 10 2 10 5 8 (<i>h</i>)=1 4 (<i>f</i> 13 13 13 13 13 13 13 13 13 13 13 13 13	2297 (P=0.C (P=0.C) (P=0.C	2599 T3-4 Events 308 19 11 79 23 61 49 28 692 49 28 692 49 28 692 49 28 N1-2 75 76 75 76 75 76 15 31 9 75 75 76 49 20 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 75 76 75 75 75 75 75 75 75 75 75 75	Total 878 878 182 289 233 119 50 128 247 103 2229 0.00000 185 136 156 108 31 71 124 50 185 108 31 71 124 52	$\label{eq:weight_interm} \begin{array}{c} \mbox{Weight} & 1 \\ 15 & 36 \\ 3 & 67 \\ 11 & 57 \\ 3 & 87 \\ 13 & 97 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 10 & 57 \\ 10 & 10 \\ 10 & 10 \\ 10 & 77 \\ 10 & 10 \\ 10 & 1$	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 554 0.27 [0.77, 057] 0.57 [0.47, 057] 0.57 [0.47, 057] 0.57 [0.44, 1.34 0.36 [0.08, 1.66 0.81 [0.44, 1.48 6 Odds Ratio H, Random, 95%; CI 1.34 [10.51, 71] 0.79 [0.74, 132] 0.99 [0.38, 2.55] 1.19 [0.74, 132] 0.21 [0.11, 0.40] 0.59 [0.24, 1.43] 0.23 [0.24, 1.43] 0.25 [0.24, 1.43] 0.27 [0.44, 1.17] 6 Odds Ratio HH, Random, 95%; 1.99 [0.12, 0.66] 0.45 [2.14, 1.47] 6	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 10 0.001 0.1 10 10 10 10 10 10 10 10 10 10 10 10 10
Total (95% CI) Total events Heterogenetic; Ch [#] =2 Test for overall effect: Study or Subgroup Toreser RA 2013 Koganemaru S 2017 ee LH 2016 Lang M 2014 Saiguss S 2016 Sh SJ 2013 Nang L 2016 total (95% CI) Total events Heterogenetic; Tau ² =C Test for overall effect: Study or Subgroup Drosser RA 2013 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2014 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2016 Lang M 2014 Lang M 2016 Lang M 2017 M 2016 Lang M 2017 M 2016 Lang M 2016 Lang M 2017 M 2016 Lang M 2016 L	1002 2029 df=1 Events 113 0 7 24 4 23 3 5 5 2 2 -0.58 <i>Ch²</i> =2 5 8 <i>Ch²</i> =0.69 (<i>F</i> 2 2 -0.58 <i>Ch²</i> =2 -0.58 <i>Ch²</i> =2 -0.59 (<i>F</i> 2 -0.59 (<i>Ch²</i>) -0.58 <i>Ch²</i> =2 -0.59 (<i>Ch²</i>) -0.58 <i>Ch²</i> =2 -0.59 (<i>Ch²</i>) -0.59 (<i>Ch²</i>) -	2297 239 53 92 43 66 40 15 15 15 15 15 568 187 77 59 568 187 77 59 239 72 138 68 120 77 120 72 138 68 120 72 138 68 120 72 138 68 120 72 138 68 120 72 138 68 120 72 138 68 15 15 15 15 15 15 15 120 72 120 72 138 68 120 72 138 68 120 72 138 120 72 138 120 72 138 120 72 138 120 72 138 120 72 138 120 72 138 120 120 72 138 120 120 72 138 120 120 120 120 120 120 120 120	259 22); <i>P</i> ² =5(T3-4 Events 308 19 11 11 79 23 61 47 9 28 6922 28 6922 6922 80 75 76 15 31 27 20 11 434 4] 47 9 75 76 15 31 27 20 15 15 31 15 31 15 31 15 31 15 31 15 31 15 31 15 31 15 31 15 15 31 15 31 15 15 31 15 15 31 15 15 31 15 15 31 15 15 15 15 15 15 15 15 15 1	Total 878 878 182 289 233 119 50 128 247 103 2229 0.00000 185 136 156 108 31 71 124 50 185 108 31 71 124 52	Weight I 15.8% 15.8% 3.6% 11.5% 13.8% 13.8% 13.8% 13.8% 8.0% 10.5% 8.0% 10.5% 10.5% 10.5% 10.5% 10.5% 10.7% 00.0% 11.7% 00.0% 11.7% 00.0% 11.7% 00.0% 11.7%	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 554 0.27 [0.77, 057] 0.57 [0.24, 1.34 0.57 [0.24, 1.34 0.57 [0.24, 1.34 0.36 [0.08, 1.66 0.81 [0.44, 1.48 6 Odds Ratio H, Random, 95%; CI 1.34 [1.05, 1.71] 0.99 [0.38, 2.55] 1.19 [0.74, 1.32 0.99 [0.38, 2.55] 1.19 [0.74, 1.52] 0.21 [0.11, 0.40] 0.58 [0.24, 1.43] 0.99 [0.38, 2.55] 1.19 [0.74, 1.52] 0.21 [0.11, 0.40] 0.59 [0.24, 1.43] 0.25 [0.12, 0.66] 0.72 [0.44, 1.17] 6 Odds Ratio	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M-H, Random, 95% Cl 0.001 0.1 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 0.001 0.1 10 10 10 10 0.001 0.1 10 10 10 10 10 10 10 10 10 10 10 10 10
Total (95% C1) Total events Heterogenetic; Ch ² =2 Terest for overall effect: Study or Suboroup Droseer RA 2013 August 2016 Li Y 2016 Lang M 2014 Lang M 2014 Lang M 2014 Lang M 2014 Lang M 2016 Total (95% C1) Total events Heterogenetic; Tau ² =C Fest for overall effect: Study or Suboroup Droseer RA 2013 Avang L 2016 Li Y 2016 Lang M 2014 Salguss 2016 Sh SJ 2013 Nang L 2015 Total events Heterogenetic; Tau ² =C Total events Heterogenetic; Tau ² =C Total events Heterogenetic; Tau ² =C Total events Heterogenetic; Tau ² =C Study or Suboroup Heterogenetic; Tau ² =C Study or Suboroup Heterogenetic (Tau ²) Heterogenetic (Tau ²)	1002 20.29, df=1 27-1.44 (<i>f</i> 113 113 13 13 5 5 5 2 2 13 13 13 5 5 5 2 2 13 13 13 13 5 5 5 2 2 10 2 10 2 10 5 8 (<i>h</i>)=1 4 2 2 13 3 10 2 10 5 8 (<i>h</i>)=1 4 (<i>f</i> 13 13 13 13 13 13 13 13 13 13 13 13 13	2297 29(P=0.C. 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 92 239 53 15 17 580 33.909, (56 15 17 568 187 120 77 59 72 120 120 15 15 17 120 120 15 17 17 120 120 120 15 15 17 120 120 120 15 16 15 120 120 120 120 120 120 120 120	2599 T3-4 Events 308 19 11 79 23 61 49 28 692 49 28 692 49 28 692 49 28 N1-2 75 76 75 76 75 76 15 31 9 75 75 76 49 20 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 75 76 75 75 75 75 75 75 75 75 75 75	Total 878 878 182 289 233 119 50 128 247 103 2229 0.00000 185 136 156 108 31 71 124 50 185 108 31 71 124 52	Weight I, 15.8% 3.6% 11.5% 3.8% 13.8% 13.8% 13.8% 13.8% 13.8% 10.5% 10.5% 10.5% 10.5% 10.5% 10.5% 10.7% 00.0% 11); \vec{f} =809 12.2% 10.1% 12.2% 10.1% 12.6% 13.1% 67.30.1% 67.30.1% 67.30.1% 67.30.1% 100.34.3	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.57 [0.41, 134 0.55 [0.18, 1.70 2.02 [0.66, 6.16 0.36 [0.08, 1.66 0.31 [0.44, 1.48 6 Odds Ratio H, Random, 95% CI 1.34 [1.05, 1.71] 0.99 [0.38, 2.55] 1.19 [0.74, 1.32 0.99 [0.38, 2.55] 1.19 [0.74, 1.32 0.21 [0.11, 0.40] 0.56 [0.24, 1.43] 0.87 [0.48, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17] 6 Odds Ratio HH, Random, 95% 1.99 [1.12, 0.66] 0.72 [0.44, 1.17] 6	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M.H. Random, 95% CI 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio M.H. Random, 95% CI 0.01 0.1 10 10 NO N1-2 CI M.H. Random, 95% CI 0.01 0.1 10 10 NO N1-2 CI M.H. Random, 95% CI
Total (95% CI) Total events Heterogenetic; Ch ² =2 Test for overall effect: Study or Suboroup Drosser RA 2013 Coganemaru S 2017 Ling M 2014 Ling M 2014 Ling M 2014 Ling M 2016 Ling M 2016 Ling M 2016 Ling M 2016 Ling M 2016 Total events Heterogenetic; Tau ² =C Total (95% CI) Total events Heterogenetic; Tau ² =C Total Suboroup Drosser RA 2013 Situ H 2015 Total (95% CI) Total events Heterogenetic; Tau ² =C Total 2017 Heterogenetic; Tau ² =C Heterogenetic; Tau ² =C Heterogene	1002 20.29, df=1 27-1.44 (<i>f</i> 113 113 13 13 5 5 5 2 2 13 13 13 5 5 5 2 2 13 13 13 13 5 5 5 2 2 10 2 10 2 10 5 8 (<i>h</i>)=1 4 2 2 13 3 10 2 10 5 8 (<i>h</i>)=1 4 (<i>f</i> 13 13 13 13 13 13 13 13 13 13 13 13 13	2297 (P=0.C (P=0.C) (P=0.C	2599 T3-4 Events 308 19 11 79 23 61 49 28 692 49 28 692 49 28 692 49 28 N1-2 75 76 75 76 75 76 15 31 9 75 75 76 49 20 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 76 N1-2 75 75 76 75 75 75 75 75 75 75 75 75 75	Total Total 878 182 283 119 500 128 247 103 2229 0.00000 Total 1 530 185 185 156 108 31 71 124 52 156 102.00000 R-deficit 52 5	$\label{eq:weight_interm} \begin{array}{c} \mbox{Weight} & 1 \\ 15 & 36 \\ 3 & 67 \\ 11 & 57 \\ 3 & 87 \\ 13 & 97 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 13 & 87 \\ 10 & 57 \\ 10 & 10 \\ 10 & 10 \\ 10 & 77 \\ 10 & 10 \\ 10 & 1$	Odds Ratio 1.66 [1.24, 22] 0.08 [0.00, 1.32 2.08 [0.78, 5.54 1.32 [0.69, 2.54 0.57 [0.41, 134 0.55 [0.18, 1.70 2.02 [0.66, 6.16 0.36 [0.08, 1.66 0.31 [0.44, 1.48 6 Odds Ratio H, Random, 95% CI 1.34 [1.05, 1.71] 0.99 [0.38, 2.55] 1.19 [0.74, 1.32 0.99 [0.38, 2.55] 1.19 [0.74, 1.32 0.21 [0.11, 0.40] 0.56 [0.24, 1.43] 0.87 [0.48, 1.59] 0.28 [0.12, 0.66] 0.72 [0.44, 1.17] 6 Odds Ratio HH, Random, 95% 1.99 [1.12, 0.66] 0.72 [0.44, 1.17] 6	0.001 0.1 10 10 Well Moderate/poor Odds Ratio M.H. Random, 95% CI 0.001 0.1 10 10 T1-2 T3-4 Odds Ratio M.H. Random, 95% CI 0.01 0.1 10 10 NO N1-2 CI M.H. Random, 95% CI 0.01 0.1 10 10 NO N1-2 CI M.H. Random, 95% CI

Figure S1 Forest plots for the association between PD-L1 expression and clinicopathological parameters. (A) Age; (B) sex; (C) tumor location; (D) tumor differentiation; (E) pT stage; (F) pN stage; and (G) MSI/MMR status.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress